<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81224</article-id><article-id pub-id-type="doi">10.7554/eLife.81224</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Computational and Systems Biology</subject></subj-group></article-categories><title-group><article-title>Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-285445"><name><surname>Sørensen</surname><given-names>Simon Grund</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5494-9375</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146975"><name><surname>Shrikhande</surname><given-names>Amruta</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285447"><name><surname>Poulsgaard</surname><given-names>Gustav Alexander</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund7"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285448"><name><surname>Christensen</surname><given-names>Mikkel Hovden</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-285449"><name><surname>Bertl</surname><given-names>Johanna</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-304397"><name><surname>Laursen</surname><given-names>Britt Elmedal</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-146976"><name><surname>Hoffmann</surname><given-names>Eva R</given-names></name><email>eva@sund.ku.dk</email><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-69524"><name><surname>Pedersen</surname><given-names>Jakob Skou</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7236-4001</contrib-id><email>jakob.skou@clin.au.dk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040r8fr65</institution-id><institution>Department of Molecular Medicine (MOMA), Aarhus University Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Aarhus</named-content></addr-line><country>Denmark</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01aj84f44</institution-id><institution>Department of Clinical Medicine, Aarhus University</institution></institution-wrap><addr-line><named-content content-type="city">Aarhus</named-content></addr-line><country>Denmark</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035b05819</institution-id><institution>DNRF Center for Chromosome Stability, Department of Cellular and Molecular Medicine, University of Copenhagen</institution></institution-wrap><addr-line><named-content content-type="city">Copenhagen</named-content></addr-line><country>Denmark</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01aj84f44</institution-id><institution>Department of Biomedicine, Aarhus University</institution></institution-wrap><addr-line><named-content content-type="city">Aarhus</named-content></addr-line><country>Denmark</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01aj84f44</institution-id><institution>Bioinformatics Research Center (BiRC), Aarhus University</institution></institution-wrap><addr-line><named-content content-type="city">Aarhus</named-content></addr-line><country>Denmark</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Rathmell</surname><given-names>W Kimryn</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dq2gs74</institution-id><institution>Vanderbilt University Medical Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rathmell</surname><given-names>W Kimryn</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dq2gs74</institution-id><institution>Vanderbilt University Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>08</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e81224</elocation-id><history><date date-type="received" iso-8601-date="2022-06-20"><day>20</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-02-26"><day>26</day><month>02</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-02-03"><day>03</day><month>02</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.01.31.478445"/></event></pub-history><permissions><copyright-statement>© 2023, Sørensen et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Sørensen et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81224-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-81224-figures-v2.pdf"/><abstract><p>DNA repair deficiencies in cancers may result in characteristic mutational patterns, as exemplified by deficiency of <italic>BRCA1/2</italic> and efficacy prediction for PARP inhibitors. We trained and evaluated predictive models for loss-of-function (LOF) of 145 individual DNA damage response genes based on genome-wide mutational patterns, including structural variants, indels, and base-substitution signatures. We identified 24 genes whose deficiency could be predicted with good accuracy, including expected mutational patterns for <italic>BRCA1/2</italic>, <italic>MSH3/6</italic>, <italic>TP53</italic>, and <italic>CDK12</italic> LOF variants. <italic>CDK12</italic> is associated with tandem duplications, and we here demonstrate that this association can accurately predict gene deficiency in prostate cancers (area under the receiver operator characteristic curve = 0.97). Our novel associations include mono- or biallelic LOF variants of <italic>ATRX</italic>, <italic>IDH1</italic>, <italic>HERC2</italic>, <italic>CDKN2A</italic>, <italic>PTEN</italic>, and <italic>SMARCA4</italic>, and our systematic approach yielded a catalogue of predictive models, which may provide targets for further research and development of treatment, and potentially help guide therapy.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Many different aspects of the environment – such as ultraviolet radiation, carcinogens in food and drink, and the ageing process itself – damage the DNA in human cells. Normally, cells can repair these sites by activating a mechanism known as the DNA damage response. However, the hundreds of genes that orchestrate this response are also themselves often lost or damaged, allowing the unrepaired sites to turn into permanent mutations that accumulate across the genome of the cancer cell.</p><p>By studying the DNA of cancer cells, it has been possible to identify characteristic patterns of mutations, called mutational signatures, that appear in different types of cancer. One specific pattern has been linked to the loss of either the <italic>BRCA1</italic> or <italic>BRCA2</italic> gene, both of which are part of the DNA damage response. However, it remained unclear how many other genes involved in the DNA damage response also lead to detectable mutational signatures when lost.</p><p>To investigate, Sørensen et al. computationally analysed data from over six thousand cancer patients. They looked for associations between over 700 DNA damage response genes and 80 different mutational signatures. As expected, the analysis revealed a strong connection between the loss of <italic>BRCA1/BRCA2</italic> and their known mutational signature. However, it also found 23 other associations between DNA damage response genes that had been lost or damaged and particular patterns of mutations in a variety of cancers. These findings suggest that mutational signatures could be used more widely to predict which DNA damage response genes are no longer functioning in the genome of cancer cells.</p><p>The mutational signature caused by the loss of <italic>BRAC1/BRAC2</italic> has been shown to make patients more responsive to a certain type of chemotherapy. Further experiments are needed to determine whether the connections identified by Sørensen et al. could also provide information on which treatment would benefit a cancer patient the most. In the future, this might help medical practitioners provide more personalized treatment.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>DNA damage response</kwd><kwd>repair deficiency</kwd><kwd>predictive modelling</kwd><kwd>personalised medicine</kwd><kwd>mutational signatures</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009708</institution-id><institution>Novo Nordisk Fonden</institution></institution-wrap></funding-source><award-id>NNF15OC0016662</award-id><principal-award-recipient><name><surname>Hoffmann</surname><given-names>Eva R</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000289</institution-id><institution>Cancer Research UK</institution></institution-wrap></funding-source><award-id>C23210/A7574</award-id><principal-award-recipient><name><surname>Hoffmann</surname><given-names>Eva R</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004836</institution-id><institution>Danmarks Frie Forskningsfond</institution></institution-wrap></funding-source><award-id>8021-00419B</award-id><principal-award-recipient><name><surname>Pedersen</surname><given-names>Jakob Skou</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008363</institution-id><institution>Kræftens Bekæmpelse</institution></institution-wrap></funding-source><award-id>R307-A17932</award-id><principal-award-recipient><name><surname>Pedersen</surname><given-names>Jakob Skou</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002739</institution-id><institution>Aarhus Universitets Forskningsfond</institution></institution-wrap></funding-source><award-id>AUFF-E-2020-6-14</award-id><principal-award-recipient><name><surname>Pedersen</surname><given-names>Jakob Skou</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100012526</institution-id><institution>Sundhedsvidenskabelige Fakultet, Aarhus Universitet</institution></institution-wrap></funding-source><award-id>PhD stipend</award-id><principal-award-recipient><name><surname>Sørensen</surname><given-names>Simon Grund</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009618</institution-id><institution>Sundhed, Region Midtjylland</institution></institution-wrap></funding-source><award-id>A2972</award-id><principal-award-recipient><name><surname>Poulsgaard</surname><given-names>Gustav Alexander</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001732</institution-id><institution>Danmarks Grundforskningsfond</institution></institution-wrap></funding-source><award-id>DNRF115</award-id><principal-award-recipient><name><surname>Hoffmann</surname><given-names>Eva R</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Deficiencies of several DNA damage response genes can be predicted by their association with genome-wide mutation patterns.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The DNA damage response (DDR) and repair pathways are central to the genetic integrity of cells, and deficiencies may cause mutational patterns genome-wide (<xref ref-type="bibr" rid="bib47">Lindahl, 1993</xref>; <xref ref-type="bibr" rid="bib55">Nik-Zainal et al., 2012</xref>; <xref ref-type="bibr" rid="bib80">Volkova et al., 2020</xref>). Some DNA repair deficiencies are known to modulate the response to therapies: <italic>BRCA1/2</italic> deficiency renders cancers susceptible to treatment with PARP inhibitors (<xref ref-type="bibr" rid="bib12">Bryant et al., 2007</xref>), mismatch repair (MMR)-deficient cancers are sensitive to checkpoint inhibitors (<xref ref-type="bibr" rid="bib42">Le et al., 2015</xref>) but resistant to alkylating agents such as temozolamide (<xref ref-type="bibr" rid="bib81">von Bueren et al., 2012</xref>), and <italic>CDK12</italic>-mutated cancers have a suggested sensitivity to CHK1 inhibitors (<xref ref-type="bibr" rid="bib60">Paculová et al., 2017</xref>). Because of this, efforts have been made to annotate inactivating mutations in DDR genes (<xref ref-type="bibr" rid="bib40">Landrum et al., 2014</xref>). However, the approach is limited by the lack of functional impact annotation of most variants, which are generally denoted as ‘variants of unknown significance’ (VUS). Moreover, loss of gene activity could also occur by other means, such as transcriptional silencing.</p><p>A complementary approach is to investigate whether DNA repair deficiencies can be identified by DNA mutational patterns, also referred to as ‘mutational scars’. This approach has been pioneered for homologous recombination deficiency (HRD) caused by <italic>BRCA1/2</italic> deficiencies (-d), which can be successfully predicted by measuring the accumulation of small deletions with neighbouring microhomologous sequences (<xref ref-type="bibr" rid="bib55">Nik-Zainal et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Davies et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Nguyen et al., 2020</xref>), such as done by the HRDetect algorithm by <xref ref-type="bibr" rid="bib19">Davies et al., 2017</xref>. The association with microhomologous deletions is due to the use of microhomology-mediated endjoining to repair double-strand breaks in homologous recombination deficient tumours (<xref ref-type="bibr" rid="bib51">McVey and Lee, 2008</xref>; <xref ref-type="bibr" rid="bib58">Nussenzweig and Nussenzweig, 2007</xref>). Likewise, MMR deficiency causes an elevated rate of mono- and dinucleotide repeat indels genome-wide, a genetic phenotype denoted microsatellite instability (MSI; <xref ref-type="bibr" rid="bib78">Umar et al., 1994</xref>; <xref ref-type="bibr" rid="bib24">Edelmann et al., 2000</xref>). Mutations in other DNA repair genes have also been associated with mutational patterns, including the tumour suppressor gene <italic>TP53</italic>, which is associated with increased structural rearrangements and whole-genome duplications (<xref ref-type="bibr" rid="bib41">Lanni and Jacks, 1998</xref>; <xref ref-type="bibr" rid="bib29">Gorgoulis et al., 2005</xref>) and <italic>CDK12</italic> which is associated with a genome-wide phenotype of large tandem duplications (<xref ref-type="bibr" rid="bib65">Popova et al., 2016</xref>; <xref ref-type="bibr" rid="bib52">Menghi et al., 2018</xref>). The scope of this approach can now be evaluated systematically across DDR genes by exploiting available whole cancer genomes from thousands of patients (<xref ref-type="bibr" rid="bib34">ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020</xref>; <xref ref-type="bibr" rid="bib66">Priestley et al., 2019</xref>).</p><p>To achieve this, mutations observed genome-wide may be condensed into mutational summary statistics for predictive modelling, including statistics based on single base subsitutions (SBSs), indels, and different types of structural variants (SVs). The SBSs are statistically assigned to so-called SBS signatures that are catalogued and enumerated within the COSMIC database (<xref ref-type="bibr" rid="bib76">Tate et al., 2019</xref>). Some of these are associated with specific DNA repair deficiencies as well as genotoxic exposures, such as ultraviolet (UV) light and smoking. Each SBS signature captures the relative frequency of the different mutation types and their flanking nucleotides (<xref ref-type="bibr" rid="bib3">Alexandrov and Stratton, 2014</xref>).</p><p>Here, we performed a systematic screen for DDR gene deficiencies that can be predicted through their association with genome-wide mutational patterns. We developed a generic approach to train predictive statistical models that identify associations with individual mutational summary statistics that capture the mutational patterns, including SBS signatures, indels, and large SVs. We applied it to 736 DDR gene deficiencies, considering both mono- and biallelic loss-of-function (LOF), identified across 32 cancer types, in a combined set of whole cancer genomes from 6065 patients (<xref ref-type="bibr" rid="bib34">ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020</xref><xref ref-type="bibr" rid="bib66">Priestley et al., 2019</xref>). The underlying aim was to identify novel associations with potential biological relevance and to evaluate whether DDR deficiencies can be predicted with sufficiently high certainty to have a potential for clinical application.</p><p>Our analysis revealed 24 DDR genes where deficiencies are associated with specific mutational summary statistics in individual cancer types across 48 predictive models. These results recapitulated the expected associations between mutational patterns and deficiencies of <italic>BRCA1/2</italic>, <italic>TP53</italic>, <italic>MSH3/6</italic>, and <italic>CDK12</italic>. We supplemented this knowledge by providing a predictive model of <italic>CDK12</italic> deficiency that achieved high accuracy (area under the receiver operator characteristic [AUROC] = 0.97) in prostate cancer. Furthermore, we present unexpected predictive models of several DDR deficiencies; <italic>ATRX</italic> and <italic>IDH1</italic> deficiency in cancers of the central nervous systems (CNSs), <italic>HERC2</italic> and <italic>CDKN2A</italic> deficiency in skin, <italic>PTEN</italic> deficiency in cancers of the CNS and uterus, and <italic>SMARCA4</italic> deficiency in cancers of unknown primary.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>DDR gene deficiencies across 6065 whole cancer genomes</title><p>We compiled and analysed 2568 whole-genome sequences (WGS) from The Pan-Cancer Analysis of Whole Genomes (PCAWG) (<xref ref-type="bibr" rid="bib34">ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020</xref>) and 3497 WGS from the Hartwig Medical Foundation (HMF) (<xref ref-type="bibr" rid="bib66">Priestley et al., 2019</xref>). In total, we investigated 6065 whole cancer genomes of 32 cancer types (<xref ref-type="fig" rid="fig1">Figure 1a</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Cancer types, DNA damage response (DDR) gene deficiencies, and mutational patterns.</title><p>(<bold>a</bold>) Cohort sizes for the 32 cancer types comprising the 6065 whole cancer genomes collected from the Hartwig Medical Foundation (HMF; <italic>n</italic> = 3497) and the PanCancer Analysis of Whole Genomes (PCAWG; <italic>n</italic> = 2568). (<bold>b</bold>) Mono- and biallelic loss-of-function (LOF) events were annotated across 736 DDR genes based on both pathogenic variants and copy number losses (loss of heterozygosity; LOH), overall and (<bold>c</bold>) per patient (<bold>d</bold>) with varying no. of LOF events per DDR gene (<italic>x</italic>-axis; logarithmic). (<bold>e</bold>) Whole-genome mutational patterns were represented as summary statistics and used as input features for the predictive models of DDR gene deficiency. Concretely, each patient was annotated with the number of single-base substitutions (SBSs) that are accounted to each SBS signature (<xref ref-type="bibr" rid="bib3">Alexandrov and Stratton, 2014</xref>; <xref ref-type="bibr" rid="bib21">Degasperi et al., 2020</xref>), number of indels divided by context (mh = microhomology; rep = repetitive), and (<bold>f</bold>) number of structural variants divided by clusterness, size, and type (del = deletion; inv = inversion; tds = tandem duplication; trans = translocation).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81224-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Loss-of-function events across tumours.</title><p>(<bold>a</bold>) Number of biallelic and (<bold>b</bold>) monoallelic loss-of-function events (<italic>x</italic>-axis) per tumour (<italic>y</italic>-axis).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81224-fig1-figsupp1-v2.tif"/></fig></fig-group><p>For each genome, we evaluated 736 known DDR genes for both germline and somatic LOF events (<xref ref-type="bibr" rid="bib61">Pearl et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Knijnenburg et al., 2018</xref>; <xref ref-type="bibr" rid="bib59">Olivieri et al., 2020</xref>). We annotated both mono- and biallelic LOF events, where each event could be either a single-nucleotide variant, an indel, or a loss-of-heterozygosity (LOH) (<xref ref-type="fig" rid="fig1">Figure 1b, c</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). Pathogenicity of SBSs and indels was evaluated using a combination of CADD scores (&gt;25; 0.3% most pathogenic variants) (<xref ref-type="bibr" rid="bib70">Rentzsch et al., 2019</xref>) and ClinVar annotation, when available (Methods).</p><p>We inferred a total of 8408 biallelic DDR gene deficiencies, primarily through a combination of somatic or germline variants (SBSs and indels) with pathogenic potential (<italic>n</italic> = 1702), or LOH events combined with a single pathogenic germline (<italic>n</italic> = 3562) or somatic (<italic>n</italic> = 3078) variant (SBS or indel; <xref ref-type="fig" rid="fig1">Figure 1b</xref>). On average we observed a single, biallelic DDR gene loss per patient, with some tumours showing extreme rates of somatic pathogenic mutations (<xref ref-type="fig" rid="fig1">Figure 1c</xref>; <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><p>As expected, <italic>TP53</italic> deficiency (<italic>TP53</italic>-d) was the most frequent LOF event (81 biallelic and 1746 monoallelic events; 29% of tumours affected; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>; <xref ref-type="fig" rid="fig1">Figure 1d</xref>), while 70% of DDR genes had biallelic deficiency in less than 10 tumours across all cancer types (511/736; <xref ref-type="fig" rid="fig1">Figure 1d</xref>). Among monoallelic events, we identified 15,063 pathogenic germline (59%) and 10,336 somatic (41%) events.</p></sec><sec id="s2-2"><title>Whole-genome mutational patterns</title><p>We collected mutational summary statistics for each cancer genome, which were used as features for the downstream predictive models (<xref ref-type="fig" rid="fig1">Figure 1e, f</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c, d</xref>). For SBSs, we evaluated exposure towards predefined sets of cohort-specific SBS signatures (<xref ref-type="bibr" rid="bib3">Alexandrov and Stratton, 2014</xref>; <xref ref-type="bibr" rid="bib21">Degasperi et al., 2020</xref>). Short indels and SVs were simply categorised and counted: Deletions were sub-categorised based on surrounding sequence repetitiveness and presence of microhomology. SVs were sub-categorised by type (tandem duplications, inversions, deletions, and translocations), five size ranges (not relevant for translocations), and cluster presence (Methods). Several SBS signatures as well as some types of indels have suggested aetiologies (collected in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>).</p></sec><sec id="s2-3"><title>Statistical modelling of DDR gene deficiencies</title><p>For the downstream statistical analysis, we restricted our focus to DDR genes in cancer types with more than five biallelic LOF events in either PCAWG or HMF (<italic>n</italic> = 194) or more than 10 monoallelic LOF events (<italic>n</italic> = 341) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f</xref>). Using <italic>BRCA2-</italic>d in the set of HMF breast cancer tumours (<italic>n</italic> = 645) as an example, we observed biallelic LOF events in 17 (2.6%; 14 germline, 3 somatic) tumours and monoallelic LOF events in 7 (1.1%; 4 germline, 3 somatic) tumours (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1g</xref>). We further observed VUS events in 53 tumours (8.2%; 42 germline, 11 somatic), which were excluded from the analysis. The remaining <italic>BRCA2</italic> wild-type (WT) tumours (<italic>n</italic> = 568; 88.1%) were used as a background set for training the predictive models (<xref ref-type="fig" rid="fig2">Figure 2a</xref>). The high fraction of germline pathogenic variants diminishes the probability of a reverse-causal relationship between the loss of <italic>BRCA2</italic> and the associated mutation patterns.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Predictive modelling of BRCA2 deficiencies in the Hartwig Medical Foundation (HMF) breast cancers.</title><p>(<bold>a</bold>) Mutational status of <italic>BRCA2</italic> across 645 HMF breast cancer patients. (<bold>b</bold>) Mutational summary statistics for the HMF breast cancer patients divided by biallelic <italic>BRCA2</italic> loss-of-function (LOF; red) and <italic>BRCA2</italic> wild-type (WT; grey) (selected predictive features in bold). (<bold>c</bold>) Predictive features and their coefficients for model of biallelic <italic>BRCA2</italic> loss with predictive performance measured in (<bold>d</bold>) area under the receiver operator characteristic (AUROC) and (<bold>e</bold>) precision-recall area-under-the-curve (PR-AUC) (PR-AUC-E = PR-AUC − baseline = 0.29; Methods). (<bold>f</bold>) Distributions of AUROC and (<bold>g</bold>) PR-AUC-E values obtained from 30,000 random data permutations compared to observed values (punctuated lines). (<bold>h</bold>) Correlation between selected predictive features (horizontal) and other highly correlated (Pearson corr. &gt;0.65) mutational features (vertical).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81224-fig2-v2.tif"/></fig><p>For each of the 535 groups of tumours we trained a least absolute shrinkage and selection operator (LASSO) regression model and evaluated the ability to discriminate between deficient and WT tumours (Methods). For <italic>BRCA2</italic>-d, we observed a strong association with the number of deletions at sites of microhomology (<xref ref-type="fig" rid="fig2">Figure 2b</xref>), with a median of 608 deletions per patient in <italic>BRCA2</italic>-d breast cancers versus 81 in <italic>BRCA2</italic> WT breast cancers, in agreement with prior findings (<xref ref-type="bibr" rid="bib55">Nik-Zainal et al., 2012</xref>; <xref ref-type="bibr" rid="bib19">Davies et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Nguyen et al., 2020</xref>). The LASSO regression also included non-clustered inversions 10–100 kb and clustered tandem duplications 1–10 kb, although both show high variance among tumours for both deficient and WT (<xref ref-type="fig" rid="fig2">Figure 2b</xref>) and have considerably smaller coefficients, ultimately contributing little influence on overall predictive performance (<xref ref-type="fig" rid="fig2">Figure 2c</xref>).</p><p>Notably, some models include features with negative coefficients. The biological interpretation would be that tumours with a certain gene deficiency have fewer mutations attributed to a particular mutation pattern. Negative features were excluded in the development of the HRDetect algorithm (<xref ref-type="bibr" rid="bib19">Davies et al., 2017</xref>), but we include them as we cannot rule out the possibility that a DDR deficiency protects from specific types of mutagenesis. Though not distinguishable in this study, we suggest that negative coefficient features may derive in three ways: First, they may stem from enhanced repair; second, they may stem from the decomposition of mutation counts into signatures; and third, the mutated tumours may represent a subclass of patients in terms of age, gender, or tumour subtype with specific mutational patterns.</p></sec><sec id="s2-4"><title>Evaluating model performance</title><p>For each model, we evaluated the predictive performance using the area-under-the-receiver-operating-curve (AUROC) score as well as the precision-recall area-under-the-curve (PR-AUC) score. The PR-AUC score is a more robust measure for unbalanced data sets (<xref ref-type="bibr" rid="bib20">Davis and Goadrich, 2006</xref>); however, the expected value for non-informative (unskilled) models equals the fraction of true positives and thus varies between models. Therefore, we used the PR-AUC enrichment over the true-positive rate (PR-AUC-E) as our selection criteria for predictive models.</p></sec><sec id="s2-5"><title>Shortlisting models</title><p>For the downstream analysis, we included (shortlisted) models with PR-AUC-E that was substantial (&gt;0.2; more than two standard deviations above the mean across all 535 models) and significant (Benjamin–Hochberg false discovery rate, FDR &lt;0.05; Monte Carlo simulations) (<xref ref-type="fig" rid="fig3">Figure 3</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Predictive models of DNA damage response (DDR) gene deficiencies.</title><p>(<bold>a</bold>) The precision-recall AUC enrichment PR-AUC-E; <italic>x</italic>-axis and significance (false discovery rate [FDR]; logarithmic <italic>y</italic>-axis) of the 535 predictive models (one model per gene with more than 5 biallelic or more than 10 tumours either mono- or biallelic mutated in either Hartwig Medical Foundation (HMF) or The Pan-Cancer Analysis of Whole Genomes (PCAWG) in any one cancer type; Methods). Significance (<italic>q</italic>-value representing FDR) evaluated by counting equally or more-extreme PR-AUC-E values across &gt;10,000 permuted data sets and applying Benjamini–Hochberg FDR control. Models with FDR below 0.05 and PR-AUC-E above 0.2 are shortlisted (Methods). (<bold>b</bold>) Shortlisted predictive models of deficiency of <italic>BRCA1</italic> or <italic>BRCA2</italic>; (<bold>c</bold>) <italic>TP53</italic> monoallelic predictive models; (<bold>d</bold>) monoallelic gene deficiency models across colorectal cancer patients; and (<bold>e</bold>) remaining gene deficiency models not contained in the other sub-groups. Numbers indicate the number of mutated out of the total number of tumours included in the development of each model.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81224-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Evaluating model performance in the opposite data set.</title><p>Predictive potential in the opposite data set, evaluated for each of the shortlisted models. The PR-AUC-E in the training data (<italic>x</italic>-axis) and opposite data (<italic>y</italic>-axis) are shown with labels for models that attain significant predictive power in the opposite data (shaded; false discovery rate &lt;0.05; 30.000 permutation tests). Shape indicates the allelic loss-of-function (LOF) event (circle biallelic and triangle monoallelic); colours indicate the data set in which the model was trained, either metastatic tumours (Hartwig Medical Foundation; HMF) or primary tumours (The Pan-Cancer Analysis of Whole Genomes; PCAWG). #LOF indicates the number of LOF mutated tumours in the opposite data set, #WT the number of non-LOF tumours.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81224-fig3-figsupp1-v2.tif"/></fig><fig id="fig3s2" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 2.</label><caption><title>Survival analysis of patients with or without loss-of-function (LOF) events in shortlisted DNA damage response (DDR) genes.</title><p>The hazard ratio (<italic>x</italic>-axis) based on overall survival between patients with or without gene LOF and its associated p-value (<italic>y</italic>-axis; −log10) evaluated using the Cox proportional hazard model for DNA damage response genes and cancer-type cohorts of the shortlisted predictive models. Models were trained on either Hartwig Medical Foundation (HMF; red) or The Pan-Cancer Analysis of Whole Genomes (PCAWG; blue) data to identify either biallelic (circle) or monoallelic (triangle) LOF. Labels are added for models with p values &lt;0.2, including the number of patients with a gene LOF event versus total number of given cancer-type cohort patients (LOF patients/total patients).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81224-fig3-figsupp2-v2.tif"/></fig><fig id="fig3s3" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 3.</label><caption><title>Kaplan–Meier survival plots for patients from cancer-type cohorts used to train the 48 shortlisted models.</title><p>Separate Kaplan–Meier plots showing the overall survival of patients with loss-of-function (LOF; red) or no-LOF (blue) in each gene for relevant cancer-type cohorts. The percentage still included in the study (<italic>y</italic>-axis) at a given timepoint (<italic>x</italic>-axis). Numbers indicate the number of patients included at a given time.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81224-fig3-figsupp3-v2.tif"/></fig></fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Predictive models with anticipated aetiology or origin.</title><p>(<bold>a</bold>) Overview of predictive models for <italic>BRCA1</italic>-d and <italic>BRCA2</italic>-d, showing data source, type of model, and loss-of-function (LOF)-set statistics. (<bold>b</bold>) PR-AUC-E, (<bold>c</bold>) area under the receiver operator characteristic (AUROC), and (<bold>d</bold>) the predictive features and their coefficient for individual models. (<bold>e–g</bold>) Overview of predictive models of <italic>TP53</italic>-d (as in a–c). (<bold>h</bold>) For each cohort, the number of structural variants (<italic>x</italic>-axis; logarithmic) for <italic>TP53</italic> LOF tumours (red) versus <italic>TP53</italic> wild-type tumours (grey) and (<bold>i</bold>) the significance of their difference (two-sided Wilcoxon rank-sum test). (<bold>j–l</bold>) Predictive models of gene deficiencies in colorectal cancers (as in a–c). (<bold>m</bold>) Number of deletions in repetitive DNA (as in h) and (<bold>n</bold>) its significance (as in i). (<bold>o</bold>) The predictive features of each model (as in d) and (<bold>p</bold>) the percentage of tumours that are co-mutated with <italic>MSH3</italic>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81224-fig4-v2.tif"/></fig></sec><sec id="s2-6"><title>Testing models in the opposite data set</title><p>Additionally, we calculated the PR-AUC-E of each model when applied to the same cohort in the opposite data set (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Due to the difference in biology between the two sets, and low numbers of LOF mutated samples, we did not use this as model performance criteria but have included the PR-AUC-E values and p values from the tests (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>). We identified significant predictive power, across both metastatic and primary cancers, for deficiency models of <italic>BRCA1/2</italic>, <italic>TP53</italic>, <italic>CDK12</italic>, <italic>PTEN</italic>, <italic>ARID1A</italic>, and <italic>IDH1A</italic>. Each case is described in the respective part of the results.</p></sec><sec id="s2-7"><title>BRCA example</title><p>In the example of <italic>BRCA2</italic>-d in breast cancers of the HMF data set, our model achieved an AUROC of 0.93 and a PR-AUC-E of 0.29 (<xref ref-type="fig" rid="fig2">Figure 2d, e</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>). Out of 30,000 permuted LOF-sets, none had a similar or higher PR-AUC score and we considered the model significant with a p-value &lt;3 × 10<sup>−5</sup> (FDR adjusted <italic>q</italic>-value &lt;6 × 10<sup>−4</sup>) (<xref ref-type="fig" rid="fig2">Figure 2f, g</xref>). The model achieved a PR-AUC-E of 0.37 when tested on the PCAWG data set, suggesting that the model may generalise across both metastatic and non-metastatic tumours. This was further supported by the independent discovery of a similar model in the PCAWG data set, which had an almost similar predictive power in the HMF data (PR-AUC-E = 0.19; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>). Notably, the <italic>BRCA2</italic>-d model did not include non-clustered deletions &lt;100 kb, SBS signature 3, and SBS signature 8, all features which have been associated with BRCAness (<xref ref-type="bibr" rid="bib19">Davies et al., 2017</xref>). However, SBS signature 3 and non-clustered deletions 1–10 kb are included in the model when the deletions at sites of microhomology are omitted from the input data set, suggesting that they are excluded during feature selection due to high positive correlation with the number of deletions at sites of microhomology among HMF breast cancers (Pearson corr. &gt;0.7; <xref ref-type="fig" rid="fig2">Figure 2h</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1i</xref>).</p><p>Our selection criteria resulted in 48 shortlisted predictive models across 24 DDR genes (<xref ref-type="fig" rid="fig3">Figure 3a</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>). As exemplified for <italic>BRCA2</italic>, each model is specified by a set of predictive features representing mutational patterns associated with DDR gene LOF. We divided the models into four groups based on aetiology and origin: models of <italic>BRCA1/2</italic>-d (eight models of <italic>BRCA2</italic>-d and a single model of <italic>BRCA1</italic>-d; <xref ref-type="fig" rid="fig3">Figure 3b</xref>); models of monoallelic <italic>TP53</italic>-d (11 models; <xref ref-type="fig" rid="fig3">Figure 3c</xref>); models of various monoallelic gene deficiencies derived from colorectal cancer patients (eight models; <xref ref-type="fig" rid="fig3">Figure 3d</xref>); and models including other DDR genes and cancer types, including previously undescribed associations (20 models; <xref ref-type="fig" rid="fig3">Figure 3e</xref>).</p></sec><sec id="s2-8"><title>Survival analysis</title><p>For each of the shortlisted models, we evaluated the difference in overall survival between samples carrying LOF mutations and those that did not. We observed nominally significant differences (p &lt; 0.05; univariate Cox regression analysis) in survival for <italic>BRCA2</italic> and <italic>TP53</italic> in multiple cancer types as well as for <italic>UVRAG</italic> in colorectal cancer (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplements 2</xref> and <xref ref-type="fig" rid="fig3s3">3</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1j</xref>). The association of <italic>TP53</italic> monoallelic LOF with decreased survival is in line with expectations (<xref ref-type="bibr" rid="bib49">Malcikova et al., 2009</xref>). Interestingly, several models of <italic>BRCA1/2</italic> LOF mutations associated with improved survival, including <italic>BRCA1</italic> LOF mutations in metastatic ovary cancers (hazard-ratio &lt;0.42; p &lt; 0.093) and <italic>BRCA2</italic> LOF mutations in non-metastatic ovary cancers (hazard-ratio &lt;0.24; p &lt; 0.017). In contrast, <italic>BRCA2</italic> LOF mutations in primary breast cancers were associated with decreased survival (hazard-ratio &gt;9.30; p &lt; 0.004) (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplements 2</xref> and <xref ref-type="fig" rid="fig3s3">3</xref>). This may potentially reflect differences in both molecular diagnostic practices and treatment regiments across these cancer types. For instance, platin-based treatment irrespective of <italic>BRCA1/2</italic> status has been standard for groups of the ovarian and pancreatic cancer patients, while traditionally not for the breast cancer patients (<xref ref-type="bibr" rid="bib28">Gennari et al., 2021</xref>; <xref ref-type="bibr" rid="bib15">Colombo et al., 2019</xref>). The sensitising effect of <italic>BRCA1/2</italic> deficiency might thus explain the associated survival differences among cancer types (<xref ref-type="bibr" rid="bib38">Kennedy et al., 2004</xref>). For most models the differences in survival were insignificant, though this may be related to the generally small set of LOF mutated samples.</p></sec><sec id="s2-9"><title>Recapitulation and predictive modelling of expected associations with <italic>BRCA1/2</italic> deficiency</title><p>Five models predicted biallelic loss of <italic>BRCA2</italic> in cancers of the ovary, prostate, pancreas, and breast. In addition, three models predicted <italic>BRCA2</italic> monoallelic loss in cancers of the pancreas, breast, and prostate. Finally, we derived a single model of biallelic <italic>BRCA1</italic> loss in ovarian cancer (<xref ref-type="fig" rid="fig3">Figures 3c</xref> and <xref ref-type="fig" rid="fig4">4a</xref>). All models significantly outperformed their Monte Carlo simulations (<italic>q</italic> &lt; 0.05; Benjamini–Hochberg FDR control) and had PR-AUC-E above 0.2 (<xref ref-type="fig" rid="fig4">Figure 4b, c</xref>).</p><p>All <italic>BRCA2</italic>-d models were predominantly predicted by deletions at sites of microhomology, consistent with the role of <italic>BRCA2</italic> in homologous recombination and suppression of microhomology-mediated endjoining (<xref ref-type="bibr" rid="bib13">Ceccaldi et al., 2015</xref>). Both clustered and non-clustered tandem duplications in the range of 1–100 kb were included as features for various models, though with much smaller predictive power. This agrees with what was identified for <italic>BRCA2</italic>-deficient tumours in prior studies (<xref ref-type="bibr" rid="bib19">Davies et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Nguyen et al., 2020</xref>). The biallelic breast cancer model based on PCAWG further included SBS signature 3 as a predictive feature (<xref ref-type="fig" rid="fig4">Figure 4d</xref>). Contrasting to the models of <italic>BRCA2</italic>-d, <italic>BRCA1-</italic>d in ovarian cancer was exclusively associated with clustered and non-clustered tandem duplications (1–10 kb; <xref ref-type="fig" rid="fig4">Figure 4d</xref>). This aligns with prior studies (<xref ref-type="bibr" rid="bib19">Davies et al., 2017</xref>; <xref ref-type="bibr" rid="bib54">Nguyen et al., 2020</xref>), which also found <italic>BRCA1</italic>-d to be closely associated with a tandem-duplicator phenotype. In general, <italic>BRCA1</italic> and <italic>BRCA2</italic> were subject to predominantly germline pathogenic events, and not a single deletion at a site of microhomology, suggesting the expected forward causality (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1g</xref>). As for the loss of <italic>BRCA2</italic>, the model for loss of <italic>BRCA1</italic> loss in ovary had sufficient predictive power (PR-AUC-E = 0.3) in the other data set, suggesting that the model works independently of the metastatic capacity of the tumour (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>).</p></sec><sec id="s2-10"><title><italic>TP53</italic> deficiencies associate with increased numbers of SVs</title><p>We detected 11 predictive models (four based on PCAWG and seven on HMF) of monoallelic <italic>TP53</italic>-d across cancers of the breast, skin, ovary, uterus, neuro-endocrine tissues, biliary gland, head and neck, pancreas, and the CNS (<xref ref-type="fig" rid="fig4">Figure 4e</xref>). These predictive models performed with PR-AUC-E values ranging from 0.21 to 0.48 in breast and biliary gland cancers, respectively. Similarly, AUROC values ranged from 0.48 to 0.88, again in breast and biliary gland cancers (<xref ref-type="fig" rid="fig4">Figure 4f, g</xref>). In line with existing literature (<xref ref-type="bibr" rid="bib31">Hanel and Moll, 2012</xref>), <italic>TP53</italic>-d is associated with a significantly increased number of SVs across the genome (Wilcoxon rank-sum test; <xref ref-type="fig" rid="fig4">Figure 4h, i</xref>), except in skin cancers. The models of <italic>TP53</italic> loss in head and neck, skin, breast, and the biliary gland performed well (PR-AUC-E above 0.2) in the other data set, suggesting that the predictive performance generalises independent of metastatic tumour state (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>).</p></sec><sec id="s2-11"><title>Colorectal cancer models derived from hypermutated MMR-deficient tumours</title><p>In the HMF colorectal cancers, we discovered eight predictive gene deficiency models (<italic>MSH3</italic>, <italic>SMC2</italic>, <italic>SMC6</italic>, <italic>BMPR2</italic>, <italic>CLASP2</italic>, <italic>SRCAP</italic>, <italic>UBR5</italic>, and <italic>UVRAG</italic>) of monoallelic LOF with PR-AUC-E ranging from 0.21 (<italic>CLASP2</italic>) to 0.62 (<italic>MSH3</italic>) (AUROC ranging from 0.68 for <italic>SRCAP</italic> deficiency to 0.94 for <italic>MSH3</italic> deficiency; <xref ref-type="fig" rid="fig4">Figure 4j–l</xref>).</p><p>We suggest that the high number of models of monoallelic deficiencies may arise from spurious LOF events in DDR genes in a subset of colorectal cancers that are hypermutated. In line with this, the hypermutated samples (<italic>n</italic> = 18; &gt;100,000 mutations) harbour 22% (5.9-fold enrichment) of all the DDR LOF events across the HMF colorectal cancer samples (<italic>n</italic> = 475).</p><p>Some colorectal cancers are signified by MMR deficiencies, such as LOF of <italic>MSH3</italic> or <italic>MSH6</italic>, creating a high number of deletions in repetitive DNA (<xref ref-type="bibr" rid="bib78">Umar et al., 1994</xref>; <xref ref-type="bibr" rid="bib24">Edelmann et al., 2000</xref>). Indeed, we found that this pattern was most profound among the <italic>MSH3</italic>-mutated cancers (<xref ref-type="fig" rid="fig4">Figure 4m, n</xref>). Furthermore, we found co-mutation with <italic>MSH3</italic> across the tumours underlying each model, ranging from 20% (<italic>SRCAP</italic>) to 33% (<italic>BMPR2</italic>) of the mutated tumours (<xref ref-type="fig" rid="fig4">Figure 4p</xref>). This suggests that the models (except for the model of <italic>MSH3</italic>-d) might be the consequence of the hypermutator phenotype. In other words, the causality may be reversed in these cases, and the mutational process driven by <italic>MSH3</italic>-d may have caused the majority of their LOF events. This notion is supported by investigating the features of the models. All eight models are characterised by a single, primary predictive feature: Insertions (<italic>SMC2</italic>, <italic>SMC6</italic>, <italic>BMPR2</italic>, <italic>UBR5</italic>, and <italic>UVRAG</italic>), deletions in repetitive DNA (<italic>MSH3</italic> and <italic>SRCAP</italic>), or deletions not flanked by repetitive or microhomologous DNA (<italic>CLASP2</italic>) (<xref ref-type="fig" rid="fig4">Figure 4o</xref>). Each of these features has a high positive correlation (Pearson corr. &gt;0.93) with the number of deletions in repetitive DNA. This correlation suggests that all eight models relate to a genome-instability phenotype, which may be driven by the <italic>MSH3</italic> co-mutated tumours or, potentially, a concurrent deficiency of other genes within the MMR system (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1i</xref>). Notably, the deficiency models of <italic>UBR5</italic>, <italic>BMPR2</italic>, <italic>CLASP2</italic>, and <italic>SMC6</italic> all had PR-AUC-E above 0.2 in the other data set, suggesting that these genes are associated with the MMR phenotype regardless of metastatic state (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>).</p></sec><sec id="s2-12"><title>Biallelic LOF of <italic>MSH6</italic> associated with increased number of deletions in repetitive DNA in prostate cancer</title><p><italic>MSH6</italic>, a gene implicated in MMR and microsatellite stability (<xref ref-type="bibr" rid="bib24">Edelmann et al., 2000</xref>), was mutated in both alleles in 7 out of 342 HMF prostate cancer patients. We observed pathogenic indels in <italic>MSH6</italic> in all seven tumours, but only one of these in mono- or dinucleotide repeat DNA. <italic>MSH6</italic> deficiency could be predicted with high accuracy (PR-AUC-E = 0.25; AUROC = 0.98) by an enrichment of deletions in repetitive DNA (<xref ref-type="fig" rid="fig5">Figure 5a, b</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>). This is consistent with existing findings of MMR deficiency and its presence in metastatic prostate cancers (<xref ref-type="bibr" rid="bib30">Graham et al., 2020</xref>).</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title><italic>CDK12</italic>-mutated prostate tumours are predicted by tandem duplications.</title><p>(<bold>a</bold>) Biallelic predictive model <italic>MSH6</italic>-d in Hartwig Medical Foundation (HMF) prostate tumours and its PR-AUC-E and area under the receiver operator characteristic (AUROC). (<bold>b</bold>) Boxplots of mutation counts between tumours that are <italic>MSH6</italic>-d loss-of-function (LOF; red) and <italic>MSH6</italic> wild-type (grey), (mutation counts are normalised and log-transformed; Methods). (<bold>c</bold>) Biallelic predictive model for <italic>CDK12</italic>-d with performance measures (as in a). (<bold>b</bold>) Boxplots of mutation counts for <italic>CDK12</italic>-d and wild-type tumours (as in b). (<bold>e</bold>) <italic>CDK12</italic>-d predictive performance for different cancer types. Predicted probability of <italic>CDK12</italic>-d (<italic>x</italic>-axis) for tumours with <italic>CDK12</italic> LOF (red) and <italic>CDK12</italic> wild-type (grey) are shown for prostate cancer, breast and ovary cancer, and all other cancer types (<italic>y</italic>-axis).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81224-fig5-v2.tif"/></fig></sec><sec id="s2-13"><title>High predictive power for <italic>CDK12</italic> deficiency</title><p><italic>CDK12</italic> encodes a kinase that regulates transcriptional and post-transcriptional processes of the DDR (<xref ref-type="bibr" rid="bib9">Blazek et al., 2011</xref>; <xref ref-type="bibr" rid="bib50">Marqués et al., 2000</xref>; <xref ref-type="bibr" rid="bib44">Li et al., 2016</xref>). We found that <italic>CDK12</italic>-d prostate cancers had an increased number of mid- and large-sized tandem duplications 100 kb to 10 Mb, compared to <italic>CDK12</italic>-WT (<xref ref-type="fig" rid="fig5">Figure 5c, d</xref>). Several studies have observed similar tandem duplication phenotypes in ovarian cancers (<xref ref-type="bibr" rid="bib65">Popova et al., 2016</xref>; <xref ref-type="bibr" rid="bib52">Menghi et al., 2018</xref>; <xref ref-type="bibr" rid="bib45">Li et al., 2020</xref>) and castration resistant prostate cancers (<xref ref-type="bibr" rid="bib82">Wu et al., 2018</xref>; <xref ref-type="bibr" rid="bib71">Rescigno et al., 2021</xref>). In agreement, nine of the 10 patients in our data set were treated with drugs associated with castration resistance (4 Enzalutamide, 3 Abiraterone, 1 Cabazitaxel, 1 Pembrolizumab) (<xref ref-type="bibr" rid="bib75">Sumanasuriya and De Bono, 2018</xref>).</p><p>Whereas the tandem duplication phenotype has been previously associated with loss of <italic>CDK12</italic>, in this study we present the first predictive algorithm utilising and quantifying the high predictive value of these patterns (PR-AUC-E = 0.73 and AUROC = 0.97). Indeed, the loss of <italic>CDK12</italic> has been demonstrated to sensitise cancer cells to CHK1— (<xref ref-type="bibr" rid="bib60">Paculová et al., 2017</xref>) and PARP inhibitors (<xref ref-type="bibr" rid="bib8">Bajrami et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">Joshi et al., 2014</xref>).</p><p>We went on to test the <italic>CDK12</italic>-d model across other cancer types (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). As expected, we observed predictive power in cancers of the ovary and breast, though at a lower level (PR-AUC-E = 0.19 and AUROC = 0.72). No predictive power was observed for the remaining cancer types. We only observed a single tumour with biallelic LOF of <italic>CDK12</italic> in PCAWG, but the predictive model was able to correctly identify this tumour, and reached a PR-AUC-E of 0.99 in the PCAWG data set.</p></sec><sec id="s2-14"><title>Novel predictive gene deficiency models</title><p>The shortlisted predictive LOF models further include biallelic LOF of <italic>ATRX</italic>, <italic>PTEN</italic>, <italic>HERC2</italic>, <italic>MEN1</italic>, <italic>SMARCA4</italic>, <italic>BAP1</italic>, and <italic>RB1</italic>, as well as monoallelic LOF of <italic>ATRX</italic>, <italic>IDH1</italic>, <italic>PTEN</italic>, <italic>CDKN2A</italic>, <italic>ARID1A</italic>, <italic>TP53BP1</italic>, <italic>HERC2</italic>, and <italic>RB1</italic> (<xref ref-type="fig" rid="fig3">Figure 3e</xref> and <xref ref-type="fig" rid="fig6">Figure 6</xref><xref ref-type="fig" rid="fig3">3</xref>,<xref ref-type="fig" rid="fig6">6</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). The number of mutated tumours underlying each model varied from 8 (biallelic <italic>SMARCA</italic>-d in cancers of unknown primary) to 22 (monoallelic <italic>HERC2</italic>-d in skin).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Novel predictive models of DNA damage response (DDR) gene deficiencies.</title><p>(<bold>a</bold>) Predictive model of <italic>ATRX</italic>-d and its PR-AUC-E, area under the receiver operator characteristic (AUROC), and selected features and their coefficients. Same information for predictive models of (<bold>b</bold>) <italic>IDH1</italic>-d, (<bold>c</bold>) <italic>SMARCA4</italic>-d, (<bold>d</bold>) <italic>CDKN2A</italic>-d, (<bold>e</bold>) <italic>HERC2</italic>-d, and (<bold>f</bold>) <italic>PTEN-</italic>d in central nervous system (CNS) cancers and (<bold>g</bold>) uterine cancers. (<bold>h</bold>) Number of single-base substitution (SBS) sig. 27 and SBS sig. 4 (<italic>y</italic>-axis; logarithmic) among tumours of unknown primary with <italic>SMARCA4</italic> biallelic loss-of-function (LOF) (red) or wild-type (grey). (<bold>i</bold>) Pearson correlation between the per-tumour number (tumours of unknown primary; Hartwig Medical Foundation [HMF]) of SBS signature 27 (<italic>y</italic>-axis) and SBS signature 4 (<italic>x</italic>-axis; logarithmic) mutations, with an overlaid linear model (blue) and its 95% confidence interval (grey). (<bold>j</bold>) Using a model trained to predict <italic>SMARCA4</italic> biallelic LOF in HMF cancers of unknown primary, we evaluate the predictive power across individual cohorts (one-tailed Wilcoxon rank-sum test), displaying significant cohorts separately (colours as in <bold>h</bold>). (k) Expression of <italic>SMARCA4,</italic> meassured as the sum of all annotated transcripts per milion (TPM; y-axis), for tumours with biallelic LOF and no LOF (x-axis). Colors indicate the rate of SBS sig. 27 in each tumour, (red &gt;0; black = 0). The difference in expression was evaluated using a non-paired Wilcoxon rank-sum test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81224-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Additional shortlisted predictive models of DNA damage response (DDR) gene deficiencies.</title><p>(<bold>a</bold>) Predictive model of <italic>ARID1A-</italic>deficiency (-d) with precision-recall area-under-the-curve enrichment from the baseline (baseline – rate of loss-of-function [LOF] in the data set; PR-AUC-E) and area-under-the-ROC curve (AUROC), as well as feature coefficients. Same info for predictive models of (<bold>b</bold>) <italic>BAP1</italic>-d, (<bold>c</bold>) <italic>MEN1-d,</italic> and (<bold>d</bold>) <italic>RB1</italic>-d<italic>.</italic></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81224-fig6-figsupp1-v2.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Monoallelic <italic>CDKN2A</italic> deficiency (-d) in The Pan-Cancer Analysis of Whole Genomes (PCAWG) and Hartwig Medical Foundation (HMF) skin cancers, mono- and biallelic <italic>HERC2</italic> deficiency in HMF skin cancers.</title><p>(<bold>a</bold>) <italic>CDKN2A</italic> monoallelic loss-of-function (LOF) cancers (red) and wild-type (grey) compared by the number of mutations (<italic>y</italic>-axis; logarithmic) across patients from the PCAWG and (<bold>b</bold>) the HMF data set (Wilcoxon rank-sum test, one-tailed). (<bold>c</bold>) Number of deletions in HMF skin cancers, <italic>HERC2-</italic>d (biallelic LOF red; monoallelic blue) and monoallelic <italic>TP53</italic>-d compared to patients with LOF of either gene (Wilcoxon test, one-tailed), and to patients with LOF in neither gene (Wilcoxon test, one-tailed). Patients with monoallelic LOF of either <italic>TP53</italic> or <italic>HERC2</italic> are compared (Wilcox. test two-tailed). Comparison of patients with LOF of both genes and patients with exclusively <italic>TP53</italic> LOF (not included; Wilcoxon test, one-tailed p = 0.049). (<bold>d</bold>) Number of single-base substitution (SBS) sig. 8 mutations in <italic>ARID1A</italic>-d prostate cancers, <italic>ARID1A</italic> wild-type cancers, and <italic>BRCA1/2</italic>-d prostate cancers (Wilcoxon test, one-tailed).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81224-fig6-figsupp2-v2.tif"/></fig></fig-group></sec><sec id="s2-15"><title>Predictive models of <italic>ATRX</italic>-d and <italic>IDH1</italic>-d in CNS cancers</title><p>We found that <italic>ATRX-</italic>d (monoallelic: PR-AUC-E = 0.21, AUROC = 0.71; biallelic: PR-AUC-E = 0.23, AUROC = 0.76; <xref ref-type="fig" rid="fig6">Figure 6a</xref>) and <italic>IDH1-</italic>d (monoallelic: PR-AUC-E = 0.24, AUROC = 0.82; <xref ref-type="fig" rid="fig6">Figure 6b</xref>) in CNS cancers were both predicted by a decreased number of SBS signature 8 mutations. In addition, <italic>ATRX-</italic>d was further predicted by non-clustered inv. 10–100 kb, although with a small coefficient and hence contributing limited discriminatory power. We discovered that 7 of 11 <italic>IDH1</italic>-mutated tumours were also <italic>ATRX</italic>-mutated (28-fold enrichment compared to <italic>IDH1</italic> WT skin cancers; p = 1.2 × 10<sup>−8</sup>, Fisher’s exact test) and that both <italic>ATRX</italic> and <italic>IDH1</italic> were predominantly hit by somatic mutations (14 of 15 for <italic>ATRX</italic>, 7 of 11 for <italic>IDH1</italic>).</p><p>Co-mutation between <italic>IDH1</italic> and <italic>ATRX</italic> is well described in gliomas (<xref ref-type="bibr" rid="bib53">Mukherjee et al., 2018</xref>). Interestingly, LOF of either gene is associated with lack of SBS signature 8, a signature associated with BRCAness (<xref ref-type="bibr" rid="bib19">Davies et al., 2017</xref>; <xref ref-type="bibr" rid="bib5">Alexandrov et al., 2020</xref>) and late-replication errors (<xref ref-type="bibr" rid="bib73">Singh et al., 2020</xref>). This suggests that CNS cancers with <italic>IDH1/ATRX</italic> deficiency are not subject to the same DNA lesions or repair processes as other CNS cancers and they may potentially belong to a separate patient subclass, though we could not identify evidence of this.</p></sec><sec id="s2-16"><title>Predictive model for <italic>SMARCA4</italic>-d in cancer of unknown primary</title><p>We discovered eight tumours (HMF) out of 77 with cancers of unknown primary with <italic>SMARCA4-</italic>d (biallelic) that could be predicted with relatively high accuracy (PR-AUC-E = 0.44; AUROC = 0.85; <xref ref-type="fig" rid="fig6">Figure 6c</xref>). These tumours showed an enrichment of SBS signature 27 [a signature first detected in myeloid cancers (<xref ref-type="bibr" rid="bib4">Alexandrov et al., 2015</xref>)], which has been suggested to be a sequencing artefact though it also displays strong strand bias (<xref ref-type="bibr" rid="bib76">Tate et al., 2019</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>). Among cancers of unknown primary, SBS signature 27 correlates strongly with SBS signature 4 (Pearson corr. = 0.96), despite the signatures different composition (cosine similarity of signatures = 0.17) (<xref ref-type="fig" rid="fig6">Figure 6h, i</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1i</xref>). This suggests that SBS signature 4 may also be associated with <italic>SMARCA4</italic>-d and we indeed found that its predictive performance (PR-AUC-E of 0.43; AUROC = 0.83) was almost equivalent to SBS signature 27. Signature 4 is associated with smoking across several cancer types (<xref ref-type="bibr" rid="bib2">Alexandrov et al., 2013</xref>; <xref ref-type="bibr" rid="bib56">Nik-Zainal et al., 2015</xref>); interestingly, <italic>SMARCA4-</italic>d is seen in aggressive thoracic sarcomas (<xref ref-type="bibr" rid="bib72">Sauter et al., 2017</xref>) and strongly enriched among patients with a history of smoking (<xref ref-type="bibr" rid="bib69">Rekhtman et al., 2020</xref>). Its gene product, BRG1, has been suggested as a lung cancer transcriptional regulator of genes that induce tumour proliferation (<xref ref-type="bibr" rid="bib18">Dagogo-Jack et al., 2020</xref>) and metastasis (<xref ref-type="bibr" rid="bib16">Concepcion et al., 2022</xref>). We evaluated the ability of SBS signature 4 to predict <italic>SMARCA4</italic>-d in other cancer types and found a significant predictive association in lung cancer, though much lower than for cancers of unknown primary (<xref ref-type="fig" rid="fig6">Figure 6j</xref>). We also found a significant ability to predict <italic>SMARCA4</italic>-d by the number of SBS signature 27 mutations in cancers of the neuro-endocrine tissues (Wilcoxon test, one-tailed p = 0.002) and head and neck (p = 4.8 × 10<sup>−7</sup>), but we could not evaluate this in lung cancers, as the signature is not among its set of cohort-specific signatures.</p><p>Twelve cancers had a high posterior probability of <italic>SMARCA4</italic>-d (<xref ref-type="fig" rid="fig6">Figure 6j</xref>) despite being <italic>SMARCA4</italic> WT and lacking pathogenic events. No other single DDR gene was mutated among all 12 tumours, with <italic>TP53</italic> having the most LOF events (6 of 12 cancers).</p><p>We evaluated the expression of <italic>SMARCA4</italic> among the cancers of unknown primary and identified a significantly lower expression of <italic>SMARCA4</italic> in tumours with biallelic LOF mutations compared to WT (p = 0.54 × 10<sup>−2</sup>; <xref ref-type="fig" rid="fig6">Figure 6k</xref>). For the 12 tumours with high signature 27 exposure but no biallelic LOF mutations, we did not observe a similar decrease in expression (<xref ref-type="fig" rid="fig6">Figure 6k</xref>), suggesting that <italic>SMARCA4</italic> was not epigenetically silenced or otherwise transcriptionally inactivated in these cases.</p><p>Given that cancers of unknown primary have disparate origins, this raises the possibility that the patients with high posterior probability of <italic>SMARCA4</italic>-d may have metastasised from a cancer type or subtype with both high levels of SBS signatures 4 and 27, as well as high incidence of <italic>SMARCA4</italic>-d. However, for the lung cancer samples, we did not observe any significant association of <italic>SMARCA4-d</italic> with subtype (p = 0.72 for HMF; p = 0.65 for PCAWG; Fisher’s exact test). Further studies are thus needed to clarify if the observed associations can be explained through such an ascertainment bias rather than causatively by <italic>SMARCA4</italic>-d.</p></sec><sec id="s2-17"><title>Predictive model for monoallelic <italic>CDKN2A</italic>-d in skin cancer</title><p>Both germline and somatic variants in <italic>CDKN2A</italic> are known to predispose for melanoma (<xref ref-type="bibr" rid="bib48">Liu et al., 1999</xref>). In the PCAWG skin cancer cohort, we found that a monoallelic predictive model of <italic>CDKN2A</italic>-d achieved relatively high accuracy (PR-AUC-E = 0.28; AUROC = 0.82). Its predictive features are enrichment of deletions at sites of microhomology, non-clustered inv. (100 kb to 1 Mb), and SBS signature 7, in order of predictive importance (<xref ref-type="fig" rid="fig6">Figure 6d</xref>). Apart from the inversions, these features are also significantly associated with biallelic <italic>CDKN2A</italic>-d in the HMF skin cancer cohort (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2a, b</xref>) and are included in the corresponding predictive model, though it had lower predictive performance (PR-AUC-E = 0.008; AUROC = 0.542) and was not shortlisted (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f</xref>). In both HMF and PCAWG, most of the observed LOF events are somatic, with the majority being biallelic (16 of 18 in PCAWG; 32 of 33 in HMF; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1g</xref>). The presence of deletions at sites of microhomology suggests a possible reduction in error-free double-stranded break repair in combination with an increased accumulation of SBS signature 7.</p></sec><sec id="s2-18"><title>Predictive model for <italic>HERC2-d</italic> in metastatic skin cancer</title><p><italic>HERC2</italic>-d has been associated with susceptibility to developing melanoma (<xref ref-type="bibr" rid="bib6">Amos et al., 2011</xref>). We found <italic>HERC2</italic>-d predictable in HMF skin cancer patients (biallelic: PR-AUC-E = 0.24, AUROC = 0.73; monoallelic: PR-AUC-E = 0.23, AUROC = 0.66; <xref ref-type="fig" rid="fig6">Figure 6e</xref>), primarily based on enrichment of deletions in non-microhomologous and non-repetitive regions.</p><p><italic>HERC2</italic> encodes a protein ligase that modulates the activity of P53 (<xref ref-type="bibr" rid="bib17">Cubillos-Rojas et al., 2014</xref>). We observed that seven of the nine tumours with biallelic <italic>HERC2</italic>-d also had a monoallelic pathogenic event in <italic>TP53</italic> (eightfold enrichment; p = 4.6 × 10<sup>−6</sup>, Fisher’s exact test). Tumours that are co-mutated in <italic>TP53</italic> (monoallelic) and <italic>HERC2</italic> (mono- or biallelic) showed a significantly higher number of deletions compared to tumours with LOF in either gene alone (Wilcoxon test, one-tailed p &lt; 0.031) and cancers that are WT for both genes (p &lt; 7.2 × 10<sup>−7</sup>) (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2c</xref>).</p></sec><sec id="s2-19"><title><italic>PTEN</italic> deficiency associates with fewer SVs in CNS and uterine cancers</title><p><italic>PTEN</italic> is a tumour suppressor gene found in various cancer types (<xref ref-type="bibr" rid="bib43">Li et al., 1997</xref>; <xref ref-type="bibr" rid="bib46">Liaw et al., 1997</xref>) and its deficiency was found to be associated with mutational patterns in uterine and CNS cancers (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>). In CNS, we acquired two identical models from the HMF data set, as we observed no monoallelic events without a second hit (mono- and biallelic PR-AUC-E = 0.37, AUROC = 0.74; <xref ref-type="fig" rid="fig6">Figure 6f</xref>). In uterine cancer, we acquired significant predictive models from both HMF and PCAWG (HMF, biallelic: PR-AUC-E = 0.37, AUROC = 0.74; HMF, monoallelic: PR-AUC-E = 0.36, AUROC = 0.79; PCAWG, monoallelic: PR-AUC-E = 0.22, AUROC = 0.74; <xref ref-type="fig" rid="fig6">Figure 6g</xref>). In addition, the models of <italic>PTEN</italic> loss in uterus had predictive power in the other data sets, suggesting signal robustness and independence of metastatic state (the PCAWG-derived model had PR-AUC-E of 0.55 in the HMF data; the HMF-derived model had a PR-AUC-E of 0.27 in PCAWG; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>). The model of biallelic <italic>PTEN</italic>-d in uterine cancers is primarily based on depletion of non-clustered inv. 10–100 kb, whereas both the HMF and PCAWG models of monoallelic deficiency are primarily based on depletion of non-clustered tandem duplications (10–100 kb) (<xref ref-type="fig" rid="fig6">Figure 6g</xref>). In contrast, our models of <italic>PTEN</italic>-d in CNS cancers from HMF were based on depletion of both non-clustered deletions 1–10 kb and non-clustered translocations (<xref ref-type="fig" rid="fig6">Figure 6f</xref>).</p></sec><sec id="s2-20"><title>Additional shortlisted gene deficiency models</title><p>We predicted monoallelic <italic>ARID1A</italic> LOF (PR-AUC-E = 0.208; AUROC = 0.72) by depletion of SBS signature 8 mutations in metastatic prostate cancer (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1a</xref>). Loss of <italic>ARID1A</italic> impairs the pausing of RNA polymerase II during transcription, leading to dysregulated gene expression (<xref ref-type="bibr" rid="bib77">Trizzino et al., 2018</xref>), whereas SBS signature 8 mutations have been associated with inactivity of <italic>BRCA1/2</italic> (<xref ref-type="bibr" rid="bib19">Davies et al., 2017</xref>). When contrasting <italic>ARID1A</italic> LOF mutated patients specifically with <italic>BRCA1/2</italic> WT patients within the prostate cancer cohort, a significant depletion of SBS signature 8 mutations remained (Wilcoxon rank-sum test p &lt; 0.0013), which expectedly increased when comparing with <italic>BRCA1/2</italic>-deficient patients (p &lt; 7.7 × 10<sup>−5</sup>; <xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2d</xref>).</p><p>We could predict the biallelic deficiency of <italic>BAP1</italic> in metastatic skin cancers (PR-AUC-E = 0.26; AUROC = 0.80) primarily by a decreased number of SBS signature 7 mutations, UV induced (<xref ref-type="bibr" rid="bib63">Pfeifer et al., 2005</xref>; <xref ref-type="bibr" rid="bib33">Howard and Tessman, 1964</xref>), and an elevated number of SBS signature 30 mutations, related to inefficient base excision repair (<xref ref-type="bibr" rid="bib23">Drost et al., 2017</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d and h</xref>; <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1b</xref>). As the two signatures have high compositional similarity (cosine similarity = 0.72), their co-occurrence and opposite predictive effects may be caused by technical difficulties with their combined inference. <italic>BAP1</italic> germline variants are commonly associated with predisposition for the development of multiple cancer types including melanoma (<xref ref-type="bibr" rid="bib64">Pilarski et al., 2020</xref>).</p><p>In metastatic neuro-endocrine cancers, biallelic loss of the <italic>MEN1</italic> gene was predicted by fewer mutations attributable to SBS signature 16, of unknown aetiology, and 9, which is related to hyperactivity of POLH (PR-AUC-E = 0.22; AUROC = 0.82) (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1c</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>). <italic>MEN1</italic> is a regulator of gene transcription and germline deficiencies are causatively associated with developing Multiple Endocrine Neoplasia Type 1 (MEN1), which is a rare, hereditary tumour condition (<xref ref-type="bibr" rid="bib14">Chandrasekharappa et al., 1997</xref>). However, in this setting, we observed only somatic events, with all 10 patients having an LOH combined with a pathogenic variant affecting the open reading frame. (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1g</xref>). Studies of somatic <italic>MEN1</italic> mutations likewise found somatic hits in <italic>MEN1</italic> exclusively together with LOH events, and associated the somatic LOF of <italic>MEN1</italic> with a different disease phenotype than that of inherited MEN1 (<xref ref-type="bibr" rid="bib32">Heppner et al., 1997</xref>).</p><p>We could predict <italic>RB1</italic> biallelic LOF among the metastatic urinary tract cancers by an increase of mutations attributable to UV-related SBS signature 7 (PR-AUC = 0.47; AUROC = 0.84) (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1d</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>). SBS signature 7 is known to develop from the exposure to UV light (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>; <xref ref-type="bibr" rid="bib33">Howard and Tessman, 1964</xref>). However, the signature has been reported by COSMIC for various cancer types with no sun exposure, including cancers of the breast, ovary, pancreas, oral cavity, lung, and uterus as well as sarcomas (<xref ref-type="bibr" rid="bib76">Tate et al., 2019</xref>). Although the predictive performance is considerable and significant, the accumulation of mutations in SBS signature 7 does not necessarily reveal the true aetiology of the underlying mutagenesis.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>The cancer-specific, incomplete repair of endogenous and exogenous DNA lesions leave specific genome-wide mutational patterns. Their detection provides potentially powerful information on the fidelity of individual DNA repair pathways and response to chemo- and immunotherapies. Taking advantage of a large pan-cancer data set, our analysis shows that mutational patterns are associated with DNA repair defects across a wide range of cancers and repair mechanisms. In this study, we have contributed concrete initial predictive algorithms for mutational patterns of several DDR gene deficiencies, with potential use for clinical intervention.</p><p>The clinical scope of our approach is exemplified by recent regulatory approval for PARPi administration, which was supported by statistical predictions of HRD based on mutational patterns (<xref ref-type="bibr" rid="bib26">FDA approval, 2019</xref>). We have similarly predicted <italic>CDK12</italic> deficiency (<italic>CDK12</italic>-d), which has previously been associated with a tandem duplication phenotype– with power similar to that of HRD detection. This suggests a clinical benefit of clinical application of predictive algorithms to test for <italic>CDK12</italic>-d, specifically when considering the application of CHK1 inhibitors in prostate, ovary, and breast cancer treatment (<xref ref-type="bibr" rid="bib60">Paculová et al., 2017</xref>).</p><p>We also find high predictive power for <italic>MSH6</italic>-d in prostate cancers by counting deletions in repetitive DNA, also known as the MSI phenotype (<xref ref-type="bibr" rid="bib10">Boland and Goel, 2010</xref>). It is common practice to search for signs of MSI in colorectal cancers, endometrial cancers, and aggressive prostate cancers. This prediction is most commonly made using a panel of repetitive DNA regions, such as the Bethesda panel (<xref ref-type="bibr" rid="bib79">Umar et al., 2004</xref>). Here we demonstrated high predictive power in prostate cancers based on mutation summary statistics, which may be routinely extracted from whole-genome sequencing. The correct identification of tumours with high MSI supports the administration of immune checkpoint blockade treatment, as the mutational phenotype leads to an increased expression of neo-peptides and thus an increased sensitivity towards the immune response (<xref ref-type="bibr" rid="bib1">Abida et al., 2019</xref>; <xref ref-type="bibr" rid="bib7">Antonarakis et al., 2019</xref>).</p><p>Our systematic approach identified a similar model of <italic>PTEN</italic> LOF in uterine cancer in the PCAWG data and the HMF data; either model also having predictive power in the other data set. The re-discovery in either data set grants further trust to this model, and further experimental investigation is warranted to understand the underlying aetiology of the mutation patterns, and the potential for clinical benefits.</p><p>Recent studies have suggested the use of CDK4/6 inhibition in treating <italic>SMARCA4</italic>-deficient tumours (<xref ref-type="bibr" rid="bib83">Xue et al., 2019</xref>). We discovered that a large subset of cancers of unknown primary (&gt;10%) have <italic>SMARCA4</italic> deficiency and that these cancers can be accurately predicted from their whole-genome accumulation of SBS signature 4 or SBS signature 27 mutations. This is a clinically challenging cancer type due to the lack of a primary cancer to guide treatment and any such prediction may serve in selecting treatment for these complex cancers, given additional experimental evaluation.</p><p>Of note, the inclusion of monoallelic events allowed for larger sets of tumours with DRR gene LOF, thereby increasing the power of our study when causative associations with mutational patterns exist. This is for instance the case for <italic>TP53</italic>, which is known to be functionally impacted by monoallelic events (<xref ref-type="bibr" rid="bib49">Malcikova et al., 2009</xref>). We shortlisted 11 models of <italic>TP53</italic>-d, which were all monoallelic. We further found that inclusion of monoallelic LOF events matched the predictive power for <italic>ATRX</italic> biallelic LOF in CNS cancers and <italic>HERC2</italic> biallelic LOF in skin cancers, suggesting that single genetic hits are sufficient to affect repair and ensuing mutational patterns for these genes.</p><p>Incorrectly annotated LOF events in DDR genes may affect both the ability to discover associations with mutational patterns and the performance of any associated predictive models. On the other hand, highly stringent LOF criteria may result in true LOF events being overlooked, and create small deficiency sets with insufficient power to discover true associations. For the annotation of germline LOF events, we restricted our focus to rare variants (population frequency ≤0.5%), as more common variants are likely benign. Given the high number of variants evaluated overall, false-positive germline LOF calls are expected. However, they are unlikely to associate with specific mutational patterns and thus are unlikely to contribute significant, shortlisted false-positive predictive models of DDR deficiency. Likewise, in cancers with hypermutator phenotypes, somatic LOF events may be caused by and associated with specific mutational patterns. This leads to predictive models that in effect detect instances of reverse causality, as discussed for the monoallelic models found in colorectal cancer. We investigated whether reverse causality was a likely explanation for an association captured by a predictive model by evaluating whether the annotated LOF events matched the predictive mutational features (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1g</xref>). In general, biallelic LOF criteria are less sensitive to wrongly annotated LOF events than monoallelic criteria, as double hits are rare compared to single hits. For both mono- and biallelic predictive models, the data permutations ensure that the observed association between the DDR gene LOF events and given mutational patterns are surprising.</p><p>Our conservative LOF curation, and a lack of expression or protein-level data, is expected to cause some LOF events to be missed. This may explain a high posterior probability of a particular gene LOF in some tumours, but no evidence of genetic disruption (as seen in <xref ref-type="fig" rid="fig5">Figures 5e</xref> and <xref ref-type="fig" rid="fig6">6h</xref>). This highlights the scope of mutation-pattern-based predictions, in particular in tumours without canonical DDR gene LOF events. At a very least, such tumours could be considered for further scrutiny for LOF of the individual DDR gene that they are predicted to have lost.</p><p>Our systematic approach provides a proof-of-concept that will become increasingly powerful as the available data sets increase in number and size. For the current data sets, consistent validation of detected associations was challenging due to small cohorts and differences in cancer biology. To establish the basis for any future synthetic lethality uses of our predictive models, it would be desirable to establish causal relationships. This has been beyond the scope of this study but could be achieved by whole-genome sequencing of cell lines or organoids with individual DDR gene knockout. Alternatively, the loss of DDR genes can be explored in animal models as previously done for several DDR genes including <italic>BRCA1/2</italic> (<xref ref-type="bibr" rid="bib25">Evers and Jonkers, 2006</xref>), MMR genes (<xref ref-type="bibr" rid="bib68">Reitmair et al., 1995</xref>; <xref ref-type="bibr" rid="bib67">Prolla et al., 1998</xref>), and <italic>TP53</italic> (<xref ref-type="bibr" rid="bib22">Donehower, 1996</xref>).</p><p>The current study yields a catalogue of predictive models that captures both known and novel associations between DDR gene deficiencies and mutational patterns. The included DDR genes may provide targets for research and development of treatment. With further optimisation, predictive models such as these may guide the selection of therapy by adding certainty of disabled or compromised repair deficiency phenotypes found in cancers of individual patients.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Data</title><p>The analysis was conducted on 6098 whole cancer genomes and included a set of 6065 whole cancer genomes after filtering (see below). The data came from two independent data sets: the PCAWG (tumours = 2583; ICGC study ID. EGAS00001001692) (<xref ref-type="bibr" rid="bib34">ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020</xref>) and the HMF (tumours = 3515; Acc. Nr. DR-044) (<xref ref-type="bibr" rid="bib66">Priestley et al., 2019</xref>). The data sets contain tumours from 32 cancer types and represent diverse patient groups in terms of age, gender, and disease history. PCAWG consists of tumours both with and without metastasis, whereas HMF exclusively consists of donors with tumours showing metastatic capability. To best relate the two data sets, all tumours are catalogued by the site of primary disease. For 77 of the metastatic HMF tumours, the primary site was unknown, and these are annotated as such (<xref ref-type="fig" rid="fig1">Figure 1a</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>).</p></sec><sec id="s4-2"><title>Curating samples</title><p>In the HMF data, we selected the earliest available sample whenever multiple samples existed for the same patient. For the PCAWG data, we used the official whitelist, obtained at the ICGC resources (<ext-link ext-link-type="uri" xlink:href="https://dcc.icgc.org/pcawg">https://dcc.icgc.org/pcawg</ext-link>), and for patients with more than one sample, we always selected the earliest, whitelisted sample available. We discarded six PCAWG samples of bone/soft tissue, as these were discarded in prior publications based on the PCAWG data set (<xref ref-type="bibr" rid="bib21">Degasperi et al., 2020</xref>) leaving 2568 PCAWG samples and 3497 HMF samples across 32 sites of the body. A list of all Donor IDs, Sample IDs, and primary sites of disease may be found in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1a</xref>.</p></sec><sec id="s4-3"><title>Curating variants for LOF annotation</title><p>We annotated variants across a set of 736 genes related to the DDR (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). The set of genes is combined from three sources, <xref ref-type="bibr" rid="bib39">Knijnenburg et al., 2018</xref>; <xref ref-type="bibr" rid="bib61">Pearl et al., 2015</xref>; and <xref ref-type="bibr" rid="bib59">Olivieri et al., 2020</xref>.</p><p>We filtered the downloaded variant call files (VCFs) of all samples for variants between the Ensembl (GRCH37/hg19) start and end position of each DDR gene (see coordinates in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1b</xref>). We included variants classified as PASS in the VCF files and variants of the PCAWG data set supported by at least two of our four variant callers. Furthermore, we discarded all variants which occurred in more than 200 samples across the two data sets in order to avoid noise arising from single-nucleotide polymorphisms (SNPs) called as single-nucleotide variants (SNVs), SNPs with high frequency in particular populations and possibly technical artefacts. We also discarded somatic variants with variant allele fractions below 0.2 and variants where gnomAD (V2.1.1) showed a germline population frequency above 0.5% (<xref ref-type="bibr" rid="bib37">Karczewski et al., 2020</xref>).</p></sec><sec id="s4-4"><title>Annotating pathogenic variants and mutations</title><p>We annotated all variants and mutations with CADD phred scores (V1.6) in order to separate likely pathogenic variants from likely benign variants (<xref ref-type="bibr" rid="bib70">Rentzsch et al., 2019</xref>). All variants with CADD phred scores of 25 or higher were considered pathogenic, whereas non-synonymous mutations with CADD phred scores below 25 and above 10 were considered VUS. Variants with CADD phred scores below 10 were considered benign. A CADD phred score of 25 is a conservative threshold (<xref ref-type="bibr" rid="bib35">Itan et al., 2016</xref>), and only includes the 0.3% most-likely pathogenic variants. In addition, we annotated all variants with their status in the ClinVar database (when present). Combining ClinVar and CADD phred scores ensured that we would be able to discover associations across all DDR genes, not only genes with ClinVar annotations, which are expected to be incomplete for any given gene.</p></sec><sec id="s4-5"><title>Annotating LOH and deep deletions</title><p>We also used the copy number profiles of each sample to discover genes with bi- or monoallelic losses of parts of genes. Any overlap between a gene and a copy number loss was indicated as an LOF event, under the assumption that losing any part of the protein-coding DNA is detrimental to the complete protein product. We considered events in which the minor allele copy number was below 0.2 to be an LOH, whereas we considered events with a total tumour copy number below 0.3 (major and minor allele summarised) as deep deletions. This cutoff is adapted from the work of <xref ref-type="bibr" rid="bib54">Nguyen et al., 2020</xref>.</p></sec><sec id="s4-6"><title>Annotating bi- and monoallelic gene hits</title><p>We considered genes with a single pathogenic variant, either somatic or germline, to be monoallelic hit (<italic>n</italic> = 25,399). In cases where the monoallelic hit is accompanied by an LOH, we considered the event a biallelic loss (<italic>n</italic> = 6,640). Finally, genes that were completely depleted in a sample were considered biallelic lost (<italic>n</italic> = 66). We did not consider a single LOH event as a monoallelic loss due to the broad impact and high frequency of such events, with ~25 times higher rates of LOH than deep deletions (<xref ref-type="fig" rid="fig1">Figure 1b, c</xref>). We have summarised the causes of LOF annotation at a per-model basis (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1g</xref>), including an annotation of the number of tumours with events hotspot locations, microhomologous DNA, and repetitive DNA. We do not disclose this information at a per-sample level in order to maintain patient privacy and data safety.</p></sec><sec id="s4-7"><title>Mutational patterns of SBSs, indels, and SVs</title><p>We summarised the genome-wide set of somatic mutations by using Signature Tools Lib, developed by <xref ref-type="bibr" rid="bib21">Degasperi et al., 2020</xref>. Firstly, we used Signature Tools Lib to count single-nucleotide variants by base change and context, and assigned these counts to a set of organ-specific signatures, as recommended by <xref ref-type="bibr" rid="bib21">Degasperi et al., 2020</xref>. We then have converted the organ-specific signature exposures to reference signature exposures using the conversion matrix found in the supplementary material of the paper by <xref ref-type="bibr" rid="bib21">Degasperi et al., 2020</xref>. For 12 signatures (N1–N12) this was not possible, and these signatures are considered to be novel. Likewise, two signatures associated with MMR deficiency, MMR1 and MMR2, are associated with several of the COSMIC MMR signatures. For these, we preserved the signature label as given by Signature Tools Lib. For cohorts with no organ-specific signatures (cancers of unknown primary, neuroendocrine tissue, thymus, urinary tract, penis, testis, small intestine, vulva, double primary, and the adrenal gland), we have assigned mutations directly to the full set of 30 reference signatures (COSMIC signatures 1–30). Note that we excluded age-related signature 1 from the modelling, as this signature confounded by acting as a proxy for the age of the patient so that the model would be learning to differentiate old from young patients rather than patients with activity of different mutational processes or repair deficiencies. We did not exclude signature 5 although it has suggested association with age, because it also has suggested associations to the hormone receptor positive subtype of breast cancers (<xref ref-type="bibr" rid="bib62">Perry et al., 2022</xref>).</p><p>Secondly, Signature Tools Lib was used to count indels: Insertions were simply counted, whereas deletions were separated by the DNA context of the deletion, being microhomologous, repetitive, or none of the two. Microhomology was defined by whether the deleted sequence was similar to the region immediately 3′ of the breakpoint, as this indicates repair by microhomology-mediated endjoining. Repetitive deletions were defined by whether there is a repeat of the indel at the 3′ end of the breakpoint (<xref ref-type="bibr" rid="bib21">Degasperi et al., 2020</xref>). We decided to not further compose indels into signatures, for the ease of interpretation; the type of deletion has a clear relation to the mechanism of repair, which is what we are investigating in this paper.</p><p>Finally, we used Signature Tools Lib to count SVs. SVs were separated into two groups, clustered and non-clustered based on the average distance between rearrangements (the inter-rearrangement distance). Regions with at least 10 breakpoints having at least 10 times smaller inter-rearrangement distance than the average across the genome of that cancer were considered clusters (<xref ref-type="bibr" rid="bib57">Nik-Zainal et al., 2016</xref>). SVs were further divided based on the type of mutation: Deletions, tandem duplications, inversions, and translocations. Deletions, tandem duplications, and inversions were further divided by size, with intervals being 1 to 10 kb, 10 to 100 kb, 100 kb to 1 Mb, 1 to 10 Mb, and finally mutations with lengths above 10 Mb. As with indels, we decided not to decompose SV counts into rearrangement signatures, to ease interpretability and because SV signatures are less established in the field. The per-sample exposure to each summary statistic may be seen in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1c</xref> (log transformed and scaled in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1d</xref>; see method below) and the suggested aetiology (when existing) may be seen in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1e</xref>; <xref ref-type="bibr" rid="bib5">Alexandrov et al., 2020</xref>; <xref ref-type="bibr" rid="bib76">Tate et al., 2019</xref>.</p></sec><sec id="s4-8"><title>Preparing subsets of data for modelling</title><p>We separated the two data sets and divided the tumours into their respective cancer-type cohorts. We stratified the data for each DDR gene; designating whether the patient had a biallelic pathogenic variant, monoallelic pathogenic variant, or no pathogenic variants. We excluded tumours with inconclusive variants (CADD phred &gt;10, &lt;25) within the gene. For modelling of cancers with biallelic variants in a gene, we selected all DDR gene-cohort combinations where more than five tumours had biallelic variants in the same gene (<italic>n</italic> = 194). Likewise, we selected all cases with more than 10 tumours with monoallelic variants (<italic>n</italic> = 341) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f</xref>). This setup means that each sample may be included in developing several models but occur only once in each model as either mutated or non-mutated. Biallelic mutated tumours were also included in the models of monoallelic loss, as we consider biallelic loss a special case of monoallelic loss.</p></sec><sec id="s4-9"><title>Generating models using LASSO regression</title><p>For each model, we calculated per-sample weights to counter the imbalance in the data, so that the weight of each sample was one minus the proportion of tumours with this mutational status (either pathogenic or non-pathogenic/WT). We then used logistic regression model with LASSO regularisation (henceforth LASSO regression), with the alpha parameter at 1, from the R-package ‘glmnet’ (v4.0) (<xref ref-type="bibr" rid="bib27">Friedman et al., 2010</xref>) to select features with predictive power. The LASSO regression was selected to achieve a sparse set of associated features that could be readily interpreted. This is in line with the methodology used in HRDetect by <xref ref-type="bibr" rid="bib19">Davies et al., 2017</xref>.</p><p>For each of <italic>k</italic> cross-fold validation sets (with <italic>k</italic> being the number of bi- or monoallelic hit tumours, respectively), we ran an LASSO regression with a nested fivefold cross-validation and the assigned weights (as mentioned above to counter imbalance in the data), to produce a set of lambda values. From the LASSO regression, we selected the lambda value corresponding to the binomial deviance which is one standard deviation away from the observed minimal binomial deviance of the regression, in order to avoid overfitting (overfitting may occur if taking the lambda of the minimal binomial deviance) (<xref ref-type="bibr" rid="bib27">Friedman et al., 2010</xref>). In a few cases, the LASSO regression converged to larger sets of features than what is justifiable by the low number of mutated tumours, and so we limited the number of features to one feature per 10 mutated tumours, rounded up and added one (e.g. 12 mutated tumours gives basis for maximum three features). For each of the <italic>k</italic> cross-folds we used the model to predict the left-out data and used these predictions for the evaluation of the model performance.</p><p>Finally, we generated a model by including the entire data set. This was done to train the best possible model in terms of selected features and coefficients, and this is the model reported in the main figures, whereas the performance measures shown in the main figures are derived from the <italic>k</italic>-fold cross-validation.</p></sec><sec id="s4-10"><title>Evaluating model predictive performance</title><p>We used <italic>k</italic>-fold cross-validation to get a measure of the predictive performance of each model. Due to the strong imbalance in the data, we use the PR-AUC enrichment from the true-positive rate (PR-AUC-E) as our statistic of performance, while also reporting traditional AUROC scores. The true-positive rate is the baseline that would be expected for a non-informed model. By subtracting the true-positive rate from the PR-AUC of each model, we can compare the performance between models despite different sample sizes.</p></sec><sec id="s4-11"><title>Model selection using Monte Carlo simulations</title><p>We selected models for further analysis (our shortlist) based on both their PR-AUC-E performance (effect size) and their significance. Across the 535 initial models, we observed a mean PR-AUC-E of 0.04 with a standard deviation of 0.099 (90%-quantile = 0.18) (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f</xref>). The PR-AUC-E threshold was set at 0.2 and thus roughly two standard deviations above the overall mean. To evaluate significance we used Monte Carlo simulations and generated a null-distribution for each of the 535 initial models. This was done by permuting the mutation state of the underlying tumours and then running the LASSO regression on the permuted data. We ran a minimum of 10,000 permutations (<italic>n</italic>) for each of the 535 models, storing the PR-AUC-E for each permutation. For models where the number (<italic>r</italic>) of permutations leading to PR-AUC-E values as or more extreme than the original model was smaller than five, we ran an additional 10,000 permutations, up to a maximum of 30,000 permutations. A p value <inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>p</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>r</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi>n</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></inline-formula> was calculated for each model (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1f</xref>). The Benjamini–Hochberg procedure was used to control the FDR and resulting adjusted p values (<italic>q</italic> values) smaller than 0.05 were shortlisted (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>). In conclusion, 48 models of 24 genes were shortlisted for further investigation.</p></sec><sec id="s4-12"><title>Evaluating model performance in the opposite data set</title><p>For each model, we evaluated the ability to predict mutations in the opposite data set, as a way to evaluate if the model is restricted to metastatic/primary tumours or not. To do this, we identified the set of mutated and WT samples in the opposite data set and used the model on each sample to acquire a posterior probability. Based on these, we calculated the PR-AUC-E of each model in the opposite data set (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1h</xref>). We permuted the mutation status of the samples 30.000 times to evaluate the significance of the PR-AUC-E of each model.</p></sec><sec id="s4-13"><title>Survival analysis</title><p>For the 48 shortlisted models, we performed a survival analysis of the underlying data (<xref ref-type="fig" rid="fig3s2">Figure 3—figure supplement 2</xref>; <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1j</xref>). For each model, we fitted a Cox-regression model estimating the hazard ratio based on overall survival as a function of the mutational status of the gene. For the PCAWG data, survival times and status were made available in the most recent data release at the ICGC/PCAWG webpage (<ext-link ext-link-type="uri" xlink:href="https://dcc.icgc.org/api/v1/download?fn=/PCAWG/clinical_and_histology/pcawg_donor_clinical_August2016_v9.xlsx">https://dcc.icgc.org/api/v1/download?fn=/PCAWG/clinical_and_histology/pcawg_donor_clinical_August2016_v9.xlsx</ext-link>). For samples with no registered survival time, we used the feature ‘donor_interval_of_last_followup’.</p><p>For the HMF data, we acquired metadata as part of the DR-282 data package. These data included biopsy date, date of death (when applicable) and treatment end date. For deceased patients, we measured the survival time from biopsy date to date of death; for the remaining patients we measured the survival time from biopsy date to treatment end date.</p></sec><sec id="s4-14"><title>Expression analysis</title><p>For the metastatic cancers of unknown primary (<italic>n</italic> = 77), we also analysed the <italic>SMARCA4</italic> expression patterns. RNAseq FASTQ files were obtained from the HMF (DR-282) for 58 of the tumours. Reads were pseudoaligned to GRCh37 transcripts from Gencode (V37lift37) and quantified using Kallisto version 0.48.0 (<xref ref-type="bibr" rid="bib11">Bray et al., 2016</xref>). For each sample, we then extracted the protein-coding <italic>SMARCA4</italic> transcripts (ENST00000644737.1) and calculated an overall gene-level TPM score as the sum of the transcript-level TPM scores.</p></sec><sec id="s4-15"><title>Code availability</title><p>The code needed to reproduce the analysis will be made available at <ext-link ext-link-type="uri" xlink:href="https://github.com/SimonGrund/DDR_Predict">https://github.com/SimonGrund/DDR_Predict</ext-link>, (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:b7a8bcef96a3427ab3cffebcd972f928b90a126f;origin=https://github.com/SimonGrund/DDR_Predict;visit=swh:1:snp:5ebc529b45f19267e9a399beedc0e74404b80f8e;anchor=swh:1:rev:c4daf1b7a9526ea411ad763c05d0c9317b45d42e">swh:1:rev:c4daf1b7a9526ea411ad763c05d0c9317b45d42e</ext-link>; <xref ref-type="bibr" rid="bib74">Sørensen, 2021</xref>) including data pre-processing, modelling of the 535 predictive models and modelling of ≥10,000 data permutation null models for each of the 535 models.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Validation, Visualization, Methodology, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Investigation, Writing - original draft</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con4"><p>Supervision, Writing - original draft</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Formal analysis</p></fn><fn fn-type="con" id="con6"><p>Supervision, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Supervision, Funding acquisition, Writing - original draft, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Supervision, Funding acquisition, Investigation, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>We analysed data generated and made available by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) as well as the Hartwig Medical Foundation (HMF). The research conforms to the principles of the Helsinki Declaration.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Supplementary tables.</title><p>(a) All included tumours and their primary tumour locations. (b) 736 DNA damage response (DDR) genes, hg19 coordinates, and the number of pathogenic events across 6065 cancer genomes. (c) All single-base substitution (SBS) signature contributions, indels counts, and structural variant (SV) counts, per sample. (d) All SBS signature contributions, indels counts, and SV counts, per sample, log-transformed and scaled to <italic>z</italic>-scores. (e) Proposed aetiologies of base substitution signatures. (f) All models (<italic>n</italic> = 535). (g) Pathogenic events in each of the 535 loss-of-function (LOF)-sets. (h) Shortlisted models (<italic>n</italic> = 48). (i) Correlation between features in shortlisted models. (j) Survival analysis for the shortlisted models.</p></caption><media xlink:href="elife-81224-supp1-v2.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-81224-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>This study is based on analyses of human germline and cancer somatic variant data. The data sets were generated and made available by the Pan-Cancer Analysis of Whole Genomes (PCAWG) consortium and from the Hartwig Medical Foundation (HMF). The majority of the data cannot be publicly accessed as it includes protected personal data, including germline variants, which cannot be made publicly available. However, accession to the underlying data sets can be achieved through applications to ICGC/TCGA and HMF as described below. The public parts of the PCAWG data set are available at <ext-link ext-link-type="uri" xlink:href="https://dcc.icgc.org/releases/PCAWG">https://dcc.icgc.org/releases/PCAWG</ext-link>, whereas controlled files may be accessed through applications to gbGaP and DACO, which should include a project proposal, as instructed on this site <ext-link ext-link-type="uri" xlink:href="https://docs.icgc.org/pcawg/data/">https://docs.icgc.org/pcawg/data/</ext-link>. The ICGC study ID of the project is EGAS00001001692. The HMF data used in this project may be found by accession code DR-044 and can be obtained by submitting an application with a project proposal to the Hartwig Medical Foundation (<ext-link ext-link-type="uri" xlink:href="https://www.hartwigmedicalfoundation.nl/en">https://www.hartwigmedicalfoundation.nl/en</ext-link>). Non-personal summary data have been supplied in supplementary tables. Supplementary table (a) All included tumours and their primary tumour locations. Supplementary table (b) 736 DDR genes, hg19 coordinates and the number ofpathogenic events across 6065 cancer genomes. Supplementary table (c) All SBS signature contributions, indels counts, and SV counts, per sample. Supplementary table (d) All SBS signature contributions, indels counts, and SV counts, per sample, log-transformed and scaled to z-scores. Supplementary table (e) Proposed Etiologies of base substitution signatures. Supplementary table (f) All models (n=535). Supplementary table (g) Pathogenic events in each of the 535 LOF-sets Supplementary table (h) Shortlisted models (n=48). Supplementary table (i) Correlation between features in shortlisted models. Supplementary table (j) Survival analysis for the shortlisted models. The third-party software used for data analysis includes: Pathogenicity annotation using CADD annotation software, which may be accessed at <ext-link ext-link-type="uri" xlink:href="https://cadd.gs.washington.edu">https://cadd.gs.washington.edu</ext-link> Signature analysis using Signature Tools Lib, which has been installed from the GitHub: <ext-link ext-link-type="uri" xlink:href="https://github.com/Nik-Zainal-Group/signature.tools.lib">https://github.com/Nik-Zainal-Group/signature.tools.lib</ext-link>, (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:777c4126db248b8b1e55660457eeaf7b2b547bb5;origin=https://github.com/Nik-Zainal-Group/signature.tools.lib;visit=swh:1:snp:611791ec596f2994c6b6f6d9f97a54b6210b8a63;anchor=swh:1:rev:af1d46750dbc2c86a60d85ef50f19f40fa33e768">swh:1:rev:af1d46750dbc2c86a60d85ef50f19f40fa33e768</ext-link>) that we developed locally for the analysis can be accessed at: <ext-link ext-link-type="uri" xlink:href="https://github.com/SimonGrund/DDR_Predict">https://github.com/SimonGrund/DDR_Predict</ext-link>, (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:b7a8bcef96a3427ab3cffebcd972f928b90a126f;origin=https://github.com/SimonGrund/DDR_Predict;visit=swh:1:snp:5ebc529b45f19267e9a399beedc0e74404b80f8e;anchor=swh:1:rev:c4daf1b7a9526ea411ad763c05d0c9317b45d42e">swh:1:rev:c4daf1b7a9526ea411ad763c05d0c9317b45d42e</ext-link>).</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank the Pan-Cancer Analysis of Whole Genomes (PCAWG), The International Cancer Genome Consortium (ICGC), and The Cancer Genome Atlas (TCGA) for access to whole cancer genomes.This publication and the underlying study have been made possible partly on the basis of the data that Hartwig Medical Foundation and the Center of Personalised Cancer Treatment (CPCT) have made available to the study. We thank Jenny Gruhn and Amy V Kaucher for valuable comments on the manuscript. We thank Dr. Andrea Degaspari for aid in using Signature Tools Lib for summarising mutation patterns.</p><p>Funding: ERH and AS were funded by the Novo Nordisk Foundation (NNF15OC0016662), Cancer Research UK (C23210/A7574), and the Danish National Research Foundation (Center grant, DNRF115). JSP, SGS, GAP, and MHC were funded by the Independent Research Fund Denmark | Medical Sciences (8021-00419B), the Danish Cancer Society (R307-A17932), Aarhus University Research Foundation (AUFF-E-2020-6-14), a PhD stipend from Aarhus University, and a stipend from Research Foundation of Central Region Denmark (A2972).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abida</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>ML</given-names></name><name><surname>Armenia</surname><given-names>J</given-names></name><name><surname>Middha</surname><given-names>S</given-names></name><name><surname>Autio</surname><given-names>KA</given-names></name><name><surname>Vargas</surname><given-names>HA</given-names></name><name><surname>Rathkopf</surname><given-names>D</given-names></name><name><surname>Morris</surname><given-names>MJ</given-names></name><name><surname>Danila</surname><given-names>DC</given-names></name><name><surname>Slovin</surname><given-names>SF</given-names></name><name><surname>Carbone</surname><given-names>E</given-names></name><name><surname>Barnett</surname><given-names>ES</given-names></name><name><surname>Hullings</surname><given-names>M</given-names></name><name><surname>Hechtman</surname><given-names>JF</given-names></name><name><surname>Zehir</surname><given-names>A</given-names></name><name><surname>Shia</surname><given-names>J</given-names></name><name><surname>Jonsson</surname><given-names>P</given-names></name><name><surname>Stadler</surname><given-names>ZK</given-names></name><name><surname>Srinivasan</surname><given-names>P</given-names></name><name><surname>Laudone</surname><given-names>VP</given-names></name><name><surname>Reuter</surname><given-names>V</given-names></name><name><surname>Wolchok</surname><given-names>JD</given-names></name><name><surname>Socci</surname><given-names>ND</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Kantoff</surname><given-names>PW</given-names></name><name><surname>Sawyers</surname><given-names>CL</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Gopalan</surname><given-names>A</given-names></name><name><surname>Scher</surname><given-names>HI</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade</article-title><source>JAMA Oncology</source><volume>5</volume><fpage>471</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2018.5801</pub-id><pub-id pub-id-type="pmid">30589920</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Aparicio</surname><given-names>SAJR</given-names></name><name><surname>Behjati</surname><given-names>S</given-names></name><name><surname>Biankin</surname><given-names>AV</given-names></name><name><surname>Bignell</surname><given-names>GR</given-names></name><name><surname>Bolli</surname><given-names>N</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>Børresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Boyault</surname><given-names>S</given-names></name><name><surname>Burkhardt</surname><given-names>B</given-names></name><name><surname>Butler</surname><given-names>AP</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>Davies</surname><given-names>HR</given-names></name><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Eils</surname><given-names>R</given-names></name><name><surname>Eyfjörd</surname><given-names>JE</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Greaves</surname><given-names>M</given-names></name><name><surname>Hosoda</surname><given-names>F</given-names></name><name><surname>Hutter</surname><given-names>B</given-names></name><name><surname>Ilicic</surname><given-names>T</given-names></name><name><surname>Imbeaud</surname><given-names>S</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><name><surname>Jäger</surname><given-names>N</given-names></name><name><surname>Jones</surname><given-names>DTW</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Knappskog</surname><given-names>S</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><name><surname>Lakhani</surname><given-names>SR</given-names></name><name><surname>López-Otín</surname><given-names>C</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Munshi</surname><given-names>NC</given-names></name><name><surname>Nakamura</surname><given-names>H</given-names></name><name><surname>Northcott</surname><given-names>PA</given-names></name><name><surname>Pajic</surname><given-names>M</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Paradiso</surname><given-names>A</given-names></name><name><surname>Pearson</surname><given-names>JV</given-names></name><name><surname>Puente</surname><given-names>XS</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Ramakrishna</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Rosenstiel</surname><given-names>P</given-names></name><name><surname>Schlesner</surname><given-names>M</given-names></name><name><surname>Schumacher</surname><given-names>TN</given-names></name><name><surname>Span</surname><given-names>PN</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Totoki</surname><given-names>Y</given-names></name><name><surname>Tutt</surname><given-names>ANJ</given-names></name><name><surname>Valdés-Mas</surname><given-names>R</given-names></name><name><surname>van Buuren</surname><given-names>MM</given-names></name><name><surname>van ’t Veer</surname><given-names>L</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Waddell</surname><given-names>N</given-names></name><name><surname>Yates</surname><given-names>LR</given-names></name><collab>Australian Pancreatic Cancer Genome Initiative</collab><collab>ICGC Breast Cancer Consortium</collab><collab>ICGC MMML-Seq Consortium</collab><collab>ICGC PedBrain</collab><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>McDermott</surname><given-names>U</given-names></name><name><surname>Lichter</surname><given-names>P</given-names></name><name><surname>Meyerson</surname><given-names>M</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name><name><surname>Siebert</surname><given-names>R</given-names></name><name><surname>Campo</surname><given-names>E</given-names></name><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Pfister</surname><given-names>SM</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Signatures of mutational processes in human cancer</article-title><source>Nature</source><volume>500</volume><fpage>415</fpage><lpage>421</lpage><pub-id pub-id-type="doi">10.1038/nature12477</pub-id><pub-id pub-id-type="pmid">23945592</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mutational signatures: the patterns of somatic mutations hidden in cancer genomes</article-title><source>Current Opinion in Genetics &amp; Development</source><volume>24</volume><fpage>52</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.gde.2013.11.014</pub-id><pub-id pub-id-type="pmid">24657537</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Jones</surname><given-names>PH</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Sale</surname><given-names>JE</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Clock-Like mutational processes in human somatic cells</article-title><source>Nature Genetics</source><volume>47</volume><fpage>1402</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1038/ng.3441</pub-id><pub-id pub-id-type="pmid">26551669</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Haradhvala</surname><given-names>NJ</given-names></name><name><surname>Huang</surname><given-names>MN</given-names></name><name><surname>Tian Ng</surname><given-names>AW</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Boot</surname><given-names>A</given-names></name><name><surname>Covington</surname><given-names>KR</given-names></name><name><surname>Gordenin</surname><given-names>DA</given-names></name><name><surname>Bergstrom</surname><given-names>EN</given-names></name><name><surname>Islam</surname><given-names>SMA</given-names></name><name><surname>Lopez-Bigas</surname><given-names>N</given-names></name><name><surname>Klimczak</surname><given-names>LJ</given-names></name><name><surname>McPherson</surname><given-names>JR</given-names></name><name><surname>Morganella</surname><given-names>S</given-names></name><name><surname>Sabarinathan</surname><given-names>R</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Mustonen</surname><given-names>V</given-names></name><collab>PCAWG Mutational Signatures Working Group</collab><name><surname>Getz</surname><given-names>G</given-names></name><name><surname>Rozen</surname><given-names>SG</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><collab>PCAWG Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>The repertoire of mutational signatures in human cancer</article-title><source>Nature</source><volume>578</volume><fpage>94</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1943-3</pub-id><pub-id pub-id-type="pmid">32025018</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Wang</surname><given-names>L-E</given-names></name><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Gershenwald</surname><given-names>JE</given-names></name><name><surname>Chen</surname><given-names>WV</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Kosoy</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Qureshi</surname><given-names>AA</given-names></name><name><surname>Vattathil</surname><given-names>S</given-names></name><name><surname>Schacherer</surname><given-names>CW</given-names></name><name><surname>Gardner</surname><given-names>JM</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Bishop</surname><given-names>DT</given-names></name><name><surname>Barrett</surname><given-names>JH</given-names></name><collab>GenoMEL Investigators</collab><name><surname>MacGregor</surname><given-names>S</given-names></name><name><surname>Hayward</surname><given-names>NK</given-names></name><name><surname>Martin</surname><given-names>NG</given-names></name><name><surname>Duffy</surname><given-names>DL</given-names></name><collab>Q-Mega Investigators</collab><name><surname>Mann</surname><given-names>GJ</given-names></name><name><surname>Cust</surname><given-names>A</given-names></name><name><surname>Hopper</surname><given-names>J</given-names></name><collab>AMFS Investigators</collab><name><surname>Brown</surname><given-names>KM</given-names></name><name><surname>Grimm</surname><given-names>EA</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Jing</surname><given-names>K</given-names></name><name><surname>McHugh</surname><given-names>C</given-names></name><name><surname>Laurie</surname><given-names>CC</given-names></name><name><surname>Doheny</surname><given-names>KF</given-names></name><name><surname>Pugh</surname><given-names>EW</given-names></name><name><surname>Seldin</surname><given-names>MF</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Genome-Wide association study identifies novel loci predisposing to cutaneous melanoma</article-title><source>Human Molecular Genetics</source><volume>20</volume><fpage>5012</fpage><lpage>5023</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddr415</pub-id><pub-id pub-id-type="pmid">21926416</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonarakis</surname><given-names>ES</given-names></name><name><surname>Shaukat</surname><given-names>F</given-names></name><name><surname>Isaacsson Velho</surname><given-names>P</given-names></name><name><surname>Kaur</surname><given-names>H</given-names></name><name><surname>Shenderov</surname><given-names>E</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Lotan</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations</article-title><source>European Urology</source><volume>75</volume><fpage>378</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.eururo.2018.10.009</pub-id><pub-id pub-id-type="pmid">30337059</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bajrami</surname><given-names>I</given-names></name><name><surname>Frankum</surname><given-names>JR</given-names></name><name><surname>Konde</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>RE</given-names></name><name><surname>Rehman</surname><given-names>FL</given-names></name><name><surname>Brough</surname><given-names>R</given-names></name><name><surname>Campbell</surname><given-names>J</given-names></name><name><surname>Sims</surname><given-names>D</given-names></name><name><surname>Rafiq</surname><given-names>R</given-names></name><name><surname>Hooper</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Kozarewa</surname><given-names>I</given-names></name><name><surname>Assiotis</surname><given-names>I</given-names></name><name><surname>Fenwick</surname><given-names>K</given-names></name><name><surname>Natrajan</surname><given-names>R</given-names></name><name><surname>Lord</surname><given-names>CJ</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Genome-Wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity</article-title><source>Cancer Research</source><volume>74</volume><fpage>287</fpage><lpage>297</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-2541</pub-id><pub-id pub-id-type="pmid">24240700</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blazek</surname><given-names>D</given-names></name><name><surname>Kohoutek</surname><given-names>J</given-names></name><name><surname>Bartholomeeusen</surname><given-names>K</given-names></name><name><surname>Johansen</surname><given-names>E</given-names></name><name><surname>Hulinkova</surname><given-names>P</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Cimermancic</surname><given-names>P</given-names></name><name><surname>Ule</surname><given-names>J</given-names></name><name><surname>Peterlin</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>The cyclin K/cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes</article-title><source>Genes &amp; Development</source><volume>25</volume><fpage>2158</fpage><lpage>2172</lpage><pub-id pub-id-type="doi">10.1101/gad.16962311</pub-id><pub-id pub-id-type="pmid">22012619</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boland</surname><given-names>CR</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Microsatellite instability in colorectal cancer</article-title><source>Gastroenterology</source><volume>138</volume><fpage>2073</fpage><lpage>2087</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.12.064</pub-id><pub-id pub-id-type="pmid">20420947</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>NL</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Melsted</surname><given-names>P</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Near-optimal probabilistic RNA-seq quantification</article-title><source>Nature Biotechnology</source><volume>34</volume><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1038/nbt0816-888d</pub-id><pub-id pub-id-type="pmid">27504780</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryant</surname><given-names>HE</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Thomas</surname><given-names>HD</given-names></name><name><surname>Parker</surname><given-names>KM</given-names></name><name><surname>Flower</surname><given-names>D</given-names></name><name><surname>Lopez</surname><given-names>E</given-names></name><name><surname>Kyle</surname><given-names>S</given-names></name><name><surname>Meuth</surname><given-names>M</given-names></name><name><surname>Curtin</surname><given-names>NJ</given-names></name><name><surname>Helleday</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase</article-title><source>Nature</source><volume>447</volume><elocation-id>346</elocation-id><pub-id pub-id-type="doi">10.1038/nature05789</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ceccaldi</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>JC</given-names></name><name><surname>Amunugama</surname><given-names>R</given-names></name><name><surname>Hajdu</surname><given-names>I</given-names></name><name><surname>Primack</surname><given-names>B</given-names></name><name><surname>Petalcorin</surname><given-names>MIR</given-names></name><name><surname>O’Connor</surname><given-names>KW</given-names></name><name><surname>Konstantinopoulos</surname><given-names>PA</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name><name><surname>Boulton</surname><given-names>SJ</given-names></name><name><surname>Yusufzai</surname><given-names>T</given-names></name><name><surname>D’Andrea</surname><given-names>AD</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Homologous-recombination-deficient tumours are dependent on polθ-mediated repair</article-title><source>Nature</source><volume>518</volume><fpage>258</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1038/nature14184</pub-id><pub-id pub-id-type="pmid">25642963</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chandrasekharappa</surname><given-names>SC</given-names></name><name><surname>Guru</surname><given-names>SC</given-names></name><name><surname>Manickam</surname><given-names>P</given-names></name><name><surname>Olufemi</surname><given-names>SE</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Emmert-Buck</surname><given-names>MR</given-names></name><name><surname>Debelenko</surname><given-names>LV</given-names></name><name><surname>Zhuang</surname><given-names>Z</given-names></name><name><surname>Lubensky</surname><given-names>IA</given-names></name><name><surname>Liotta</surname><given-names>LA</given-names></name><name><surname>Crabtree</surname><given-names>JS</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Roe</surname><given-names>BA</given-names></name><name><surname>Weisemann</surname><given-names>J</given-names></name><name><surname>Boguski</surname><given-names>MS</given-names></name><name><surname>Agarwal</surname><given-names>SK</given-names></name><name><surname>Kester</surname><given-names>MB</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Heppner</surname><given-names>C</given-names></name><name><surname>Dong</surname><given-names>Q</given-names></name><name><surname>Spiegel</surname><given-names>AM</given-names></name><name><surname>Burns</surname><given-names>AL</given-names></name><name><surname>Marx</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Positional cloning of the gene for multiple endocrine neoplasia-type 1</article-title><source>Science</source><volume>276</volume><fpage>404</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1126/science.276.5311.404</pub-id><pub-id pub-id-type="pmid">9103196</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>N</given-names></name><name><surname>Sessa</surname><given-names>C</given-names></name><name><surname>du Bois</surname><given-names>A</given-names></name><name><surname>Ledermann</surname><given-names>J</given-names></name><name><surname>McCluggage</surname><given-names>WG</given-names></name><name><surname>McNeish</surname><given-names>I</given-names></name><name><surname>Morice</surname><given-names>P</given-names></name><name><surname>Pignata</surname><given-names>S</given-names></name><name><surname>Ray-Coquard</surname><given-names>I</given-names></name><name><surname>Vergote</surname><given-names>I</given-names></name><name><surname>Baert</surname><given-names>T</given-names></name><name><surname>Belaroussi</surname><given-names>I</given-names></name><name><surname>Dashora</surname><given-names>A</given-names></name><name><surname>Olbrecht</surname><given-names>S</given-names></name><name><surname>Planchamp</surname><given-names>F</given-names></name><name><surname>Querleu</surname><given-names>D</given-names></name><collab>ESMO-ESGO Ovarian Cancer Consensus Conference Working Group</collab></person-group><year iso-8601-date="2019">2019</year><article-title>ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†</article-title><source>Annals of Oncology</source><volume>30</volume><fpage>672</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdz062</pub-id><pub-id pub-id-type="pmid">31046081</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Concepcion</surname><given-names>CP</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>LaFave</surname><given-names>LM</given-names></name><name><surname>Bhutkar</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>DeAngelo</surname><given-names>LP</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Del Priore</surname><given-names>I</given-names></name><name><surname>Schoenfeld</surname><given-names>AJ</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Kartha</surname><given-names>VK</given-names></name><name><surname>Westcott</surname><given-names>PMK</given-names></name><name><surname>Sánchez-Rivera</surname><given-names>FJ</given-names></name><name><surname>Meli</surname><given-names>K</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Bronson</surname><given-names>RT</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Rekhtman</surname><given-names>N</given-names></name><name><surname>Rudin</surname><given-names>CM</given-names></name><name><surname>Kim</surname><given-names>CF</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Buenrostro</surname><given-names>JD</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Smarca4 inactivation promotes lineage-specific transformation and early metastatic features in the lung</article-title><source>Cancer Discovery</source><volume>12</volume><fpage>562</fpage><lpage>585</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-0248</pub-id><pub-id pub-id-type="pmid">34561242</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cubillos-Rojas</surname><given-names>M</given-names></name><name><surname>Amair-Pinedo</surname><given-names>F</given-names></name><name><surname>Peiró-Jordán</surname><given-names>R</given-names></name><name><surname>Bartrons</surname><given-names>R</given-names></name><name><surname>Ventura</surname><given-names>F</given-names></name><name><surname>Rosa</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The E3 ubiquitin protein ligase HERC2 modulates the activity of tumor protein p53 by regulating its oligomerization</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>14782</fpage><lpage>14795</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.527978</pub-id><pub-id pub-id-type="pmid">24722987</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dagogo-Jack</surname><given-names>I</given-names></name><name><surname>Schrock</surname><given-names>AB</given-names></name><name><surname>Kem</surname><given-names>M</given-names></name><name><surname>Jessop</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Ross</surname><given-names>JS</given-names></name><name><surname>Lennerz</surname><given-names>JK</given-names></name><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Mino-Kenudson</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Clinicopathologic characteristics of BRG1-deficient NSCLC</article-title><source>Journal of Thoracic Oncology</source><volume>15</volume><fpage>766</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2020.01.002</pub-id><pub-id pub-id-type="pmid">31988001</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Glodzik</surname><given-names>D</given-names></name><name><surname>Morganella</surname><given-names>S</given-names></name><name><surname>Yates</surname><given-names>LR</given-names></name><name><surname>Staaf</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Ramakrishna</surname><given-names>M</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Boyault</surname><given-names>S</given-names></name><name><surname>Sieuwerts</surname><given-names>AM</given-names></name><name><surname>Simpson</surname><given-names>PT</given-names></name><name><surname>King</surname><given-names>TA</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Eyfjord</surname><given-names>JE</given-names></name><name><surname>Kong</surname><given-names>G</given-names></name><name><surname>Borg</surname><given-names>Å</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>Børresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Martens</surname><given-names>JWM</given-names></name><name><surname>Span</surname><given-names>PN</given-names></name><name><surname>Lakhani</surname><given-names>SR</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Tutt</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>AM</given-names></name><name><surname>Van Laere</surname><given-names>S</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Viari</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures</article-title><source>Nature Medicine</source><volume>23</volume><fpage>517</fpage><lpage>525</lpage><pub-id pub-id-type="doi">10.1038/nm.4292</pub-id><pub-id pub-id-type="pmid">28288110</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>J</given-names></name><name><surname>Goadrich</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The relationship between Precision-Recall and ROC curves</article-title><conf-name>23rd international conference</conf-name><conf-loc>Pittsburgh, Pennsylvania</conf-loc><pub-id pub-id-type="doi">10.1145/1143844.1143874</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degasperi</surname><given-names>A</given-names></name><name><surname>Amarante</surname><given-names>TD</given-names></name><name><surname>Czarnecki</surname><given-names>J</given-names></name><name><surname>Shooter</surname><given-names>S</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Glodzik</surname><given-names>D</given-names></name><name><surname>Morganella</surname><given-names>S</given-names></name><name><surname>Nanda</surname><given-names>AS</given-names></name><name><surname>Badja</surname><given-names>C</given-names></name><name><surname>Koh</surname><given-names>G</given-names></name><name><surname>Momen</surname><given-names>SE</given-names></name><name><surname>Georgakopoulos-Soares</surname><given-names>I</given-names></name><name><surname>Dias</surname><given-names>JML</given-names></name><name><surname>Young</surname><given-names>J</given-names></name><name><surname>Memari</surname><given-names>Y</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A practical framework and online tool for mutational signature analyses show Inter-tissue variation and driver dependencies</article-title><source>Nature Cancer</source><volume>1</volume><fpage>249</fpage><lpage>263</lpage><pub-id pub-id-type="doi">10.1038/s43018-020-0027-5</pub-id><pub-id pub-id-type="pmid">32118208</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donehower</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>The p53-deficient mouse: a model for basic and applied cancer studies</article-title><source>Seminars in Cancer Biology</source><volume>7</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1006/scbi.1996.0035</pub-id><pub-id pub-id-type="pmid">9110404</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drost</surname><given-names>J</given-names></name><name><surname>van Boxtel</surname><given-names>R</given-names></name><name><surname>Blokzijl</surname><given-names>F</given-names></name><name><surname>Mizutani</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>N</given-names></name><name><surname>Sasselli</surname><given-names>V</given-names></name><name><surname>de Ligt</surname><given-names>J</given-names></name><name><surname>Behjati</surname><given-names>S</given-names></name><name><surname>Grolleman</surname><given-names>JE</given-names></name><name><surname>van Wezel</surname><given-names>T</given-names></name><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Kuiper</surname><given-names>RP</given-names></name><name><surname>Cuppen</surname><given-names>E</given-names></name><name><surname>Clevers</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer</article-title><source>Science</source><volume>358</volume><fpage>234</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1126/science.aao3130</pub-id><pub-id pub-id-type="pmid">28912133</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edelmann</surname><given-names>W</given-names></name><name><surname>Umar</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Heyer</surname><given-names>J</given-names></name><name><surname>Kucherlapati</surname><given-names>M</given-names></name><name><surname>Lia</surname><given-names>M</given-names></name><name><surname>Kneitz</surname><given-names>B</given-names></name><name><surname>Avdievich</surname><given-names>E</given-names></name><name><surname>Fan</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name><name><surname>Crouse</surname><given-names>G</given-names></name><name><surname>Kunkel</surname><given-names>T</given-names></name><name><surname>Lipkin</surname><given-names>M</given-names></name><name><surname>Kolodner</surname><given-names>RD</given-names></name><name><surname>Kucherlapati</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The DNA mismatch repair genes MSH3 and MSH6 cooperate in intestinal tumor suppression</article-title><source>Cancer Research</source><volume>60</volume><fpage>803</fpage><lpage>807</lpage><pub-id pub-id-type="pmid">10706084</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evers</surname><given-names>B</given-names></name><name><surname>Jonkers</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects</article-title><source>Oncogene</source><volume>25</volume><fpage>5885</fpage><lpage>5897</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1209871</pub-id><pub-id pub-id-type="pmid">16998503</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="web"><person-group person-group-type="author"><collab>FDA approval</collab></person-group><year iso-8601-date="2019">2019</year><article-title>FDA approves niraparib for HRD-positive advanced ovarian cancer</article-title><ext-link ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer</ext-link><date-in-citation iso-8601-date="2022-05-17">May 17, 2022</date-in-citation></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedman</surname><given-names>J</given-names></name><name><surname>Hastie</surname><given-names>T</given-names></name><name><surname>Tibshirani</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Regularization paths for generalized linear models via coordinate descent</article-title><source>Journal of Statistical Software</source><volume>33</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20808728</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gennari</surname><given-names>A</given-names></name><name><surname>André</surname><given-names>F</given-names></name><name><surname>Barrios</surname><given-names>CH</given-names></name><name><surname>Cortés</surname><given-names>J</given-names></name><name><surname>de Azambuja</surname><given-names>E</given-names></name><name><surname>DeMichele</surname><given-names>A</given-names></name><name><surname>Dent</surname><given-names>R</given-names></name><name><surname>Fenlon</surname><given-names>D</given-names></name><name><surname>Gligorov</surname><given-names>J</given-names></name><name><surname>Hurvitz</surname><given-names>SA</given-names></name><name><surname>Im</surname><given-names>SA</given-names></name><name><surname>Krug</surname><given-names>D</given-names></name><name><surname>Kunz</surname><given-names>WG</given-names></name><name><surname>Loi</surname><given-names>S</given-names></name><name><surname>Penault-Llorca</surname><given-names>F</given-names></name><name><surname>Ricke</surname><given-names>J</given-names></name><name><surname>Robson</surname><given-names>M</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Saura</surname><given-names>C</given-names></name><name><surname>Schmid</surname><given-names>P</given-names></name><name><surname>Singer</surname><given-names>CF</given-names></name><name><surname>Spanic</surname><given-names>T</given-names></name><name><surname>Tolaney</surname><given-names>SM</given-names></name><name><surname>Turner</surname><given-names>NC</given-names></name><name><surname>Curigliano</surname><given-names>G</given-names></name><name><surname>Loibl</surname><given-names>S</given-names></name><name><surname>Paluch-Shimon</surname><given-names>S</given-names></name><name><surname>Harbeck</surname><given-names>N</given-names></name><collab>ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org</collab></person-group><year iso-8601-date="2021">2021</year><article-title>ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer</article-title><source>Annals of Oncology</source><volume>32</volume><fpage>1475</fpage><lpage>1495</lpage><pub-id pub-id-type="doi">10.1016/j.annonc.2021.09.019</pub-id><pub-id pub-id-type="pmid">34678411</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorgoulis</surname><given-names>VG</given-names></name><name><surname>Vassiliou</surname><given-names>L-VF</given-names></name><name><surname>Karakaidos</surname><given-names>P</given-names></name><name><surname>Zacharatos</surname><given-names>P</given-names></name><name><surname>Kotsinas</surname><given-names>A</given-names></name><name><surname>Liloglou</surname><given-names>T</given-names></name><name><surname>Venere</surname><given-names>M</given-names></name><name><surname>Ditullio</surname><given-names>RA</given-names><suffix>Jr</suffix></name><name><surname>Kastrinakis</surname><given-names>NG</given-names></name><name><surname>Levy</surname><given-names>B</given-names></name><name><surname>Kletsas</surname><given-names>D</given-names></name><name><surname>Yoneta</surname><given-names>A</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name><name><surname>Kittas</surname><given-names>C</given-names></name><name><surname>Halazonetis</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions</article-title><source>Nature</source><volume>434</volume><fpage>907</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.1038/nature03485</pub-id><pub-id pub-id-type="pmid">15829965</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>LS</given-names></name><name><surname>Montgomery</surname><given-names>B</given-names></name><name><surname>Cheng</surname><given-names>HH</given-names></name><name><surname>Yu</surname><given-names>EY</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Pritchard</surname><given-names>C</given-names></name><name><surname>Erickson</surname><given-names>S</given-names></name><name><surname>Alva</surname><given-names>A</given-names></name><name><surname>Schweizer</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mismatch repair deficiency in metastatic prostate cancer: response to PD-1 blockade and standard therapies</article-title><source>PLOS ONE</source><volume>15</volume><elocation-id>e0233260</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0233260</pub-id><pub-id pub-id-type="pmid">32453797</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanel</surname><given-names>W</given-names></name><name><surname>Moll</surname><given-names>UM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Links between mutant p53 and genomic instability</article-title><source>Journal of Cellular Biochemistry</source><volume>113</volume><fpage>433</fpage><lpage>439</lpage><pub-id pub-id-type="doi">10.1002/jcb.23400</pub-id><pub-id pub-id-type="pmid">22006292</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heppner</surname><given-names>C</given-names></name><name><surname>Kester</surname><given-names>MB</given-names></name><name><surname>Agarwal</surname><given-names>SK</given-names></name><name><surname>Debelenko</surname><given-names>LV</given-names></name><name><surname>Emmert-Buck</surname><given-names>MR</given-names></name><name><surname>Guru</surname><given-names>SC</given-names></name><name><surname>Manickam</surname><given-names>P</given-names></name><name><surname>Olufemi</surname><given-names>SE</given-names></name><name><surname>Skarulis</surname><given-names>MC</given-names></name><name><surname>Doppman</surname><given-names>JL</given-names></name><name><surname>Alexander</surname><given-names>RH</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Saggar</surname><given-names>SK</given-names></name><name><surname>Lubensky</surname><given-names>IA</given-names></name><name><surname>Zhuang</surname><given-names>Z</given-names></name><name><surname>Liotta</surname><given-names>LA</given-names></name><name><surname>Chandrasekharappa</surname><given-names>SC</given-names></name><name><surname>Collins</surname><given-names>FS</given-names></name><name><surname>Spiegel</surname><given-names>AM</given-names></name><name><surname>Burns</surname><given-names>AL</given-names></name><name><surname>Marx</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Somatic mutation of the MEN1 gene in parathyroid tumours</article-title><source>Nature Genetics</source><volume>16</volume><fpage>375</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1038/ng0897-375</pub-id><pub-id pub-id-type="pmid">9241276</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Howard</surname><given-names>BD</given-names></name><name><surname>Tessman</surname><given-names>I</given-names></name></person-group><year iso-8601-date="1964">1964</year><article-title>Identification of the altered bases in mutated single-stranded DNA</article-title><source>Journal of Molecular Biology</source><volume>9</volume><fpage>372</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/S0022-2836(64)80214-X</pub-id><pub-id pub-id-type="pmid">14202273</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Pan-cancer analysis of whole genomes</article-title><source>Nature</source><volume>578</volume><fpage>82</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-1969-6</pub-id><pub-id pub-id-type="pmid">32025007</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Itan</surname><given-names>Y</given-names></name><name><surname>Shang</surname><given-names>L</given-names></name><name><surname>Boisson</surname><given-names>B</given-names></name><name><surname>Ciancanelli</surname><given-names>MJ</given-names></name><name><surname>Markle</surname><given-names>JG</given-names></name><name><surname>Martinez-Barricarte</surname><given-names>R</given-names></name><name><surname>Scott</surname><given-names>E</given-names></name><name><surname>Shah</surname><given-names>I</given-names></name><name><surname>Stenson</surname><given-names>PD</given-names></name><name><surname>Gleeson</surname><given-names>J</given-names></name><name><surname>Cooper</surname><given-names>DN</given-names></name><name><surname>Quintana-Murci</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>S-Y</given-names></name><name><surname>Abel</surname><given-names>L</given-names></name><name><surname>Casanova</surname><given-names>J-L</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The mutation significance cutoff: gene-level thresholds for variant predictions</article-title><source>Nature Methods</source><volume>13</volume><fpage>109</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1038/nmeth.3739</pub-id><pub-id pub-id-type="pmid">26820543</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>PM</given-names></name><name><surname>Sutor</surname><given-names>SL</given-names></name><name><surname>Huntoon</surname><given-names>CJ</given-names></name><name><surname>Karnitz</surname><given-names>LM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly (ADP-ribose) polymerase inhibitors</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>9247</fpage><lpage>9253</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.551143</pub-id><pub-id pub-id-type="pmid">24554720</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Francioli</surname><given-names>LC</given-names></name><name><surname>Tiao</surname><given-names>G</given-names></name><name><surname>Cummings</surname><given-names>BB</given-names></name><name><surname>Alföldi</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Collins</surname><given-names>RL</given-names></name><name><surname>Laricchia</surname><given-names>KM</given-names></name><name><surname>Ganna</surname><given-names>A</given-names></name><name><surname>Birnbaum</surname><given-names>DP</given-names></name><name><surname>Gauthier</surname><given-names>LD</given-names></name><name><surname>Brand</surname><given-names>H</given-names></name><name><surname>Solomonson</surname><given-names>M</given-names></name><name><surname>Watts</surname><given-names>NA</given-names></name><name><surname>Rhodes</surname><given-names>D</given-names></name><name><surname>Singer-Berk</surname><given-names>M</given-names></name><name><surname>England</surname><given-names>EM</given-names></name><name><surname>Seaby</surname><given-names>EG</given-names></name><name><surname>Kosmicki</surname><given-names>JA</given-names></name><name><surname>Walters</surname><given-names>RK</given-names></name><name><surname>Tashman</surname><given-names>K</given-names></name><name><surname>Farjoun</surname><given-names>Y</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Poterba</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Seed</surname><given-names>C</given-names></name><name><surname>Whiffin</surname><given-names>N</given-names></name><name><surname>Chong</surname><given-names>JX</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Pierce-Hoffman</surname><given-names>E</given-names></name><name><surname>Zappala</surname><given-names>Z</given-names></name><name><surname>O’Donnell-Luria</surname><given-names>AH</given-names></name><name><surname>Minikel</surname><given-names>EV</given-names></name><name><surname>Weisburd</surname><given-names>B</given-names></name><name><surname>Lek</surname><given-names>M</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Vittal</surname><given-names>C</given-names></name><name><surname>Armean</surname><given-names>IM</given-names></name><name><surname>Bergelson</surname><given-names>L</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Connolly</surname><given-names>KM</given-names></name><name><surname>Covarrubias</surname><given-names>M</given-names></name><name><surname>Donnelly</surname><given-names>S</given-names></name><name><surname>Ferriera</surname><given-names>S</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Gentry</surname><given-names>J</given-names></name><name><surname>Gupta</surname><given-names>N</given-names></name><name><surname>Jeandet</surname><given-names>T</given-names></name><name><surname>Kaplan</surname><given-names>D</given-names></name><name><surname>Llanwarne</surname><given-names>C</given-names></name><name><surname>Munshi</surname><given-names>R</given-names></name><name><surname>Novod</surname><given-names>S</given-names></name><name><surname>Petrillo</surname><given-names>N</given-names></name><name><surname>Roazen</surname><given-names>D</given-names></name><name><surname>Ruano-Rubio</surname><given-names>V</given-names></name><name><surname>Saltzman</surname><given-names>A</given-names></name><name><surname>Schleicher</surname><given-names>M</given-names></name><name><surname>Soto</surname><given-names>J</given-names></name><name><surname>Tibbetts</surname><given-names>K</given-names></name><name><surname>Tolonen</surname><given-names>C</given-names></name><name><surname>Wade</surname><given-names>G</given-names></name><name><surname>Talkowski</surname><given-names>ME</given-names></name><collab>Genome Aggregation Database Consortium</collab><name><surname>Neale</surname><given-names>BM</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>MacArthur</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title><source>Nature</source><volume>581</volume><fpage>434</fpage><lpage>443</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2308-7</pub-id><pub-id pub-id-type="pmid">32461654</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>RD</given-names></name><name><surname>Quinn</surname><given-names>JE</given-names></name><name><surname>Mullan</surname><given-names>PB</given-names></name><name><surname>Johnston</surname><given-names>PG</given-names></name><name><surname>Harkin</surname><given-names>DP</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The role of BRCA1 in the cellular response to chemotherapy</article-title><source>Journal of the National Cancer Institute</source><volume>96</volume><fpage>1659</fpage><lpage>1668</lpage><pub-id pub-id-type="doi">10.1093/jnci/djh312</pub-id><pub-id pub-id-type="pmid">15547178</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knijnenburg</surname><given-names>TA</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zimmermann</surname><given-names>MT</given-names></name><name><surname>Chambwe</surname><given-names>N</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Way</surname><given-names>GP</given-names></name><name><surname>Greene</surname><given-names>CS</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Akbani</surname><given-names>R</given-names></name><name><surname>Feng</surname><given-names>B</given-names></name><name><surname>Donehower</surname><given-names>LA</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Karimi</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>P</given-names></name><name><surname>Jia</surname><given-names>P</given-names></name><name><surname>Shinbrot</surname><given-names>E</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Bailey</surname><given-names>MH</given-names></name><name><surname>Yau</surname><given-names>C</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Weinstein</surname><given-names>JN</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Laird</surname><given-names>PW</given-names></name><name><surname>Wheeler</surname><given-names>DA</given-names></name><name><surname>Shmulevich</surname><given-names>I</given-names></name><name><surname>Monnat</surname><given-names>RJ</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas</article-title><source>Cell Reports</source><volume>23</volume><fpage>239</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.03.076</pub-id><pub-id pub-id-type="pmid">29617664</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landrum</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Riley</surname><given-names>GR</given-names></name><name><surname>Jang</surname><given-names>W</given-names></name><name><surname>Rubinstein</surname><given-names>WS</given-names></name><name><surname>Church</surname><given-names>DM</given-names></name><name><surname>Maglott</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>ClinVar: public archive of relationships among sequence variation and human phenotype</article-title><source>Nucleic Acids Research</source><volume>42</volume><fpage>D980</fpage><lpage>D985</lpage><pub-id pub-id-type="doi">10.1093/nar/gkt1113</pub-id><pub-id pub-id-type="pmid">24234437</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanni</surname><given-names>JS</given-names></name><name><surname>Jacks</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Characterization of the p53-dependent postmitotic checkpoint following spindle disruption</article-title><source>Molecular and Cellular Biology</source><volume>18</volume><fpage>1055</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1128/MCB.18.2.1055</pub-id><pub-id pub-id-type="pmid">9448003</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>DT</given-names></name><name><surname>Uram</surname><given-names>JN</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Bartlett</surname><given-names>BR</given-names></name><name><surname>Kemberling</surname><given-names>H</given-names></name><name><surname>Eyring</surname><given-names>AD</given-names></name><name><surname>Skora</surname><given-names>AD</given-names></name><name><surname>Luber</surname><given-names>BS</given-names></name><name><surname>Azad</surname><given-names>NS</given-names></name><name><surname>Laheru</surname><given-names>D</given-names></name><name><surname>Biedrzycki</surname><given-names>B</given-names></name><name><surname>Donehower</surname><given-names>RC</given-names></name><name><surname>Zaheer</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>GA</given-names></name><name><surname>Crocenzi</surname><given-names>TS</given-names></name><name><surname>Lee</surname><given-names>JJ</given-names></name><name><surname>Duffy</surname><given-names>SM</given-names></name><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>de la Chapelle</surname><given-names>A</given-names></name><name><surname>Koshiji</surname><given-names>M</given-names></name><name><surname>Bhaijee</surname><given-names>F</given-names></name><name><surname>Huebner</surname><given-names>T</given-names></name><name><surname>Hruban</surname><given-names>RH</given-names></name><name><surname>Wood</surname><given-names>LD</given-names></name><name><surname>Cuka</surname><given-names>N</given-names></name><name><surname>Pardoll</surname><given-names>DM</given-names></name><name><surname>Papadopoulos</surname><given-names>N</given-names></name><name><surname>Kinzler</surname><given-names>KW</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Cornish</surname><given-names>TC</given-names></name><name><surname>Taube</surname><given-names>JM</given-names></name><name><surname>Anders</surname><given-names>RA</given-names></name><name><surname>Eshleman</surname><given-names>JR</given-names></name><name><surname>Vogelstein</surname><given-names>B</given-names></name><name><surname>Diaz</surname><given-names>LA</given-names><suffix>Jr</suffix></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pd-1 blockade in tumors with mismatch-repair deficiency</article-title><source>The New England Journal of Medicine</source><volume>372</volume><fpage>2509</fpage><lpage>2520</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1500596</pub-id><pub-id pub-id-type="pmid">26028255</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yen</surname><given-names>C</given-names></name><name><surname>Liaw</surname><given-names>D</given-names></name><name><surname>Podsypanina</surname><given-names>K</given-names></name><name><surname>Bose</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>SI</given-names></name><name><surname>Puc</surname><given-names>J</given-names></name><name><surname>Miliaresis</surname><given-names>C</given-names></name><name><surname>Rodgers</surname><given-names>L</given-names></name><name><surname>McCombie</surname><given-names>R</given-names></name><name><surname>Bigner</surname><given-names>SH</given-names></name><name><surname>Giovanella</surname><given-names>BC</given-names></name><name><surname>Ittmann</surname><given-names>M</given-names></name><name><surname>Tycko</surname><given-names>B</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Wigler</surname><given-names>MH</given-names></name><name><surname>Parsons</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer</article-title><source>Science</source><volume>275</volume><fpage>1943</fpage><lpage>1947</lpage><pub-id pub-id-type="doi">10.1126/science.275.5308.1943</pub-id><pub-id pub-id-type="pmid">9072974</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chatterjee</surname><given-names>N</given-names></name><name><surname>Spirohn</surname><given-names>K</given-names></name><name><surname>Boutros</surname><given-names>M</given-names></name><name><surname>Bohmann</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cdk12 is a gene-selective RNA polymerase II kinase that regulates a subset of the transcriptome, including nrf2 target genes</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>21455</elocation-id><pub-id pub-id-type="doi">10.1038/srep21455</pub-id><pub-id pub-id-type="pmid">26911346</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Roberts</surname><given-names>ND</given-names></name><name><surname>Wala</surname><given-names>JA</given-names></name><name><surname>Shapira</surname><given-names>O</given-names></name><name><surname>Schumacher</surname><given-names>SE</given-names></name><name><surname>Kumar</surname><given-names>K</given-names></name><name><surname>Khurana</surname><given-names>E</given-names></name><name><surname>Waszak</surname><given-names>S</given-names></name><name><surname>Korbel</surname><given-names>JO</given-names></name><name><surname>Haber</surname><given-names>JE</given-names></name><name><surname>Imielinski</surname><given-names>M</given-names></name><collab>PCAWG Structural Variation Working Group</collab><name><surname>Weischenfeldt</surname><given-names>J</given-names></name><name><surname>Beroukhim</surname><given-names>R</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><collab>PCAWG Consortium</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Patterns of somatic structural variation in human cancer genomes</article-title><source>Nature</source><volume>578</volume><fpage>112</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1913-9</pub-id><pub-id pub-id-type="pmid">32025012</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liaw</surname><given-names>D</given-names></name><name><surname>Marsh</surname><given-names>DJ</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Dahia</surname><given-names>PL</given-names></name><name><surname>Wang</surname><given-names>SI</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Bose</surname><given-names>S</given-names></name><name><surname>Call</surname><given-names>KM</given-names></name><name><surname>Tsou</surname><given-names>HC</given-names></name><name><surname>Peacocke</surname><given-names>M</given-names></name><name><surname>Eng</surname><given-names>C</given-names></name><name><surname>Parsons</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome</article-title><source>Nature Genetics</source><volume>16</volume><fpage>64</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1038/ng0597-64</pub-id><pub-id pub-id-type="pmid">9140396</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindahl</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Instability and decay of the primary structure of DNA</article-title><source>Nature</source><volume>362</volume><fpage>709</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1038/362709a0</pub-id><pub-id pub-id-type="pmid">8469282</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Dilworth</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Monzon</surname><given-names>J</given-names></name><name><surname>Summers</surname><given-names>A</given-names></name><name><surname>Lassam</surname><given-names>N</given-names></name><name><surname>Hogg</surname><given-names>D</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mutation of the CDKN2A 5’ UTR creates an aberrant initiation codon and predisposes to melanoma</article-title><source>Nature Genetics</source><volume>21</volume><fpage>128</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/5082</pub-id><pub-id pub-id-type="pmid">9916806</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malcikova</surname><given-names>J</given-names></name><name><surname>Smardova</surname><given-names>J</given-names></name><name><surname>Rocnova</surname><given-names>L</given-names></name><name><surname>Tichy</surname><given-names>B</given-names></name><name><surname>Kuglik</surname><given-names>P</given-names></name><name><surname>Vranova</surname><given-names>V</given-names></name><name><surname>Cejkova</surname><given-names>S</given-names></name><name><surname>Svitakova</surname><given-names>M</given-names></name><name><surname>Skuhrova Francova</surname><given-names>H</given-names></name><name><surname>Brychtova</surname><given-names>Y</given-names></name><name><surname>Doubek</surname><given-names>M</given-names></name><name><surname>Brejcha</surname><given-names>M</given-names></name><name><surname>Klabusay</surname><given-names>M</given-names></name><name><surname>Mayer</surname><given-names>J</given-names></name><name><surname>Pospisilova</surname><given-names>S</given-names></name><name><surname>Trbusek</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage</article-title><source>Blood</source><volume>114</volume><fpage>5307</fpage><lpage>5314</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-07-234708</pub-id><pub-id pub-id-type="pmid">19850740</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marqués</surname><given-names>F</given-names></name><name><surname>Moreau</surname><given-names>JL</given-names></name><name><surname>Peaucellier</surname><given-names>G</given-names></name><name><surname>Lozano</surname><given-names>JC</given-names></name><name><surname>Schatt</surname><given-names>P</given-names></name><name><surname>Picard</surname><given-names>A</given-names></name><name><surname>Callebaut</surname><given-names>I</given-names></name><name><surname>Perret</surname><given-names>E</given-names></name><name><surname>Genevière</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A new subfamily of high molecular mass CDC2-related kinases with PITAI/VRE motifs</article-title><source>Biochemical and Biophysical Research Communications</source><volume>279</volume><fpage>832</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.4042</pub-id><pub-id pub-id-type="pmid">11162436</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McVey</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>MMEJ repair of double-strand breaks (director’s cut): deleted sequences and alternative endings</article-title><source>Trends in Genetics</source><volume>24</volume><fpage>529</fpage><lpage>538</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2008.08.007</pub-id><pub-id pub-id-type="pmid">18809224</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Menghi</surname><given-names>F</given-names></name><name><surname>Barthel</surname><given-names>FP</given-names></name><name><surname>Yadav</surname><given-names>V</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Ji</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Carter</surname><given-names>GW</given-names></name><name><surname>Ruan</surname><given-names>Y</given-names></name><name><surname>Scully</surname><given-names>R</given-names></name><name><surname>Verhaak</surname><given-names>RGW</given-names></name><name><surname>Jonkers</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The tandem duplicator phenotype is a prevalent genome-wide cancer configuration driven by distinct gene mutations</article-title><source>Cancer Cell</source><volume>34</volume><fpage>197</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.06.008</pub-id><pub-id pub-id-type="pmid">30017478</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>J</given-names></name><name><surname>Johannessen</surname><given-names>T-C</given-names></name><name><surname>Ohba</surname><given-names>S</given-names></name><name><surname>Chow</surname><given-names>TT</given-names></name><name><surname>Jones</surname><given-names>L</given-names></name><name><surname>Pandita</surname><given-names>A</given-names></name><name><surname>Pieper</surname><given-names>RO</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere phenotype in glioma</article-title><source>Cancer Research</source><volume>78</volume><fpage>2966</fpage><lpage>2977</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-2269</pub-id><pub-id pub-id-type="pmid">29545335</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>W M Martens</surname><given-names>J</given-names></name><name><surname>Van Hoeck</surname><given-names>A</given-names></name><name><surname>Cuppen</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pan-cancer landscape of homologous recombination deficiency</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5584</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19406-4</pub-id><pub-id pub-id-type="pmid">33149131</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Greenman</surname><given-names>CD</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>D</given-names></name><name><surname>Hinton</surname><given-names>J</given-names></name><name><surname>Marshall</surname><given-names>J</given-names></name><name><surname>Stebbings</surname><given-names>LA</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Leroy</surname><given-names>C</given-names></name><name><surname>Ramakrishna</surname><given-names>M</given-names></name><name><surname>Rance</surname><given-names>R</given-names></name><name><surname>Lau</surname><given-names>KW</given-names></name><name><surname>Mudie</surname><given-names>LJ</given-names></name><name><surname>Varela</surname><given-names>I</given-names></name><name><surname>McBride</surname><given-names>DJ</given-names></name><name><surname>Bignell</surname><given-names>GR</given-names></name><name><surname>Cooke</surname><given-names>SL</given-names></name><name><surname>Shlien</surname><given-names>A</given-names></name><name><surname>Gamble</surname><given-names>J</given-names></name><name><surname>Whitmore</surname><given-names>I</given-names></name><name><surname>Maddison</surname><given-names>M</given-names></name><name><surname>Tarpey</surname><given-names>PS</given-names></name><name><surname>Davies</surname><given-names>HR</given-names></name><name><surname>Papaemmanuil</surname><given-names>E</given-names></name><name><surname>Stephens</surname><given-names>PJ</given-names></name><name><surname>McLaren</surname><given-names>S</given-names></name><name><surname>Butler</surname><given-names>AP</given-names></name><name><surname>Teague</surname><given-names>JW</given-names></name><name><surname>Jönsson</surname><given-names>G</given-names></name><name><surname>Garber</surname><given-names>JE</given-names></name><name><surname>Silver</surname><given-names>D</given-names></name><name><surname>Miron</surname><given-names>P</given-names></name><name><surname>Fatima</surname><given-names>A</given-names></name><name><surname>Boyault</surname><given-names>S</given-names></name><name><surname>Langerød</surname><given-names>A</given-names></name><name><surname>Tutt</surname><given-names>A</given-names></name><name><surname>Martens</surname><given-names>JWM</given-names></name><name><surname>Aparicio</surname><given-names>SAJR</given-names></name><name><surname>Borg</surname><given-names>Å</given-names></name><name><surname>Salomon</surname><given-names>AV</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Børresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Neuberger</surname><given-names>MS</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><collab>Breast Cancer Working Group of the International Cancer Genome Consortium</collab></person-group><year iso-8601-date="2012">2012</year><article-title>Mutational processes molding the genomes of 21 breast cancers</article-title><source>Cell</source><volume>149</volume><fpage>979</fpage><lpage>993</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.04.024</pub-id><pub-id pub-id-type="pmid">22608084</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Kucab</surname><given-names>JE</given-names></name><name><surname>Morganella</surname><given-names>S</given-names></name><name><surname>Glodzik</surname><given-names>D</given-names></name><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Arlt</surname><given-names>VM</given-names></name><name><surname>Weninger</surname><given-names>A</given-names></name><name><surname>Hollstein</surname><given-names>M</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Phillips</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The genome as a record of environmental exposure</article-title><source>Mutagenesis</source><volume>30</volume><fpage>763</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1093/mutage/gev073</pub-id><pub-id pub-id-type="pmid">26443852</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nik-Zainal</surname><given-names>S</given-names></name><name><surname>Davies</surname><given-names>H</given-names></name><name><surname>Staaf</surname><given-names>J</given-names></name><name><surname>Ramakrishna</surname><given-names>M</given-names></name><name><surname>Glodzik</surname><given-names>D</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Martincorena</surname><given-names>I</given-names></name><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Martin</surname><given-names>S</given-names></name><name><surname>Wedge</surname><given-names>DC</given-names></name><name><surname>Van Loo</surname><given-names>P</given-names></name><name><surname>Ju</surname><given-names>YS</given-names></name><name><surname>Smid</surname><given-names>M</given-names></name><name><surname>Brinkman</surname><given-names>AB</given-names></name><name><surname>Morganella</surname><given-names>S</given-names></name><name><surname>Aure</surname><given-names>MR</given-names></name><name><surname>Lingjærde</surname><given-names>OC</given-names></name><name><surname>Langerød</surname><given-names>A</given-names></name><name><surname>Ringnér</surname><given-names>M</given-names></name><name><surname>Ahn</surname><given-names>S-M</given-names></name><name><surname>Boyault</surname><given-names>S</given-names></name><name><surname>Brock</surname><given-names>JE</given-names></name><name><surname>Broeks</surname><given-names>A</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Desmedt</surname><given-names>C</given-names></name><name><surname>Dirix</surname><given-names>L</given-names></name><name><surname>Dronov</surname><given-names>S</given-names></name><name><surname>Fatima</surname><given-names>A</given-names></name><name><surname>Foekens</surname><given-names>JA</given-names></name><name><surname>Gerstung</surname><given-names>M</given-names></name><name><surname>Hooijer</surname><given-names>GKJ</given-names></name><name><surname>Jang</surname><given-names>SJ</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Kim</surname><given-names>H-Y</given-names></name><name><surname>King</surname><given-names>TA</given-names></name><name><surname>Krishnamurthy</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>J-Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>McLaren</surname><given-names>S</given-names></name><name><surname>Menzies</surname><given-names>A</given-names></name><name><surname>Mustonen</surname><given-names>V</given-names></name><name><surname>O’Meara</surname><given-names>S</given-names></name><name><surname>Pauporté</surname><given-names>I</given-names></name><name><surname>Pivot</surname><given-names>X</given-names></name><name><surname>Purdie</surname><given-names>CA</given-names></name><name><surname>Raine</surname><given-names>K</given-names></name><name><surname>Ramakrishnan</surname><given-names>K</given-names></name><name><surname>Rodríguez-González</surname><given-names>FG</given-names></name><name><surname>Romieu</surname><given-names>G</given-names></name><name><surname>Sieuwerts</surname><given-names>AM</given-names></name><name><surname>Simpson</surname><given-names>PT</given-names></name><name><surname>Shepherd</surname><given-names>R</given-names></name><name><surname>Stebbings</surname><given-names>L</given-names></name><name><surname>Stefansson</surname><given-names>OA</given-names></name><name><surname>Teague</surname><given-names>J</given-names></name><name><surname>Tommasi</surname><given-names>S</given-names></name><name><surname>Treilleux</surname><given-names>I</given-names></name><name><surname>Van den Eynden</surname><given-names>GG</given-names></name><name><surname>Vermeulen</surname><given-names>P</given-names></name><name><surname>Vincent-Salomon</surname><given-names>A</given-names></name><name><surname>Yates</surname><given-names>L</given-names></name><name><surname>Caldas</surname><given-names>C</given-names></name><name><surname>van’t Veer</surname><given-names>L</given-names></name><name><surname>Tutt</surname><given-names>A</given-names></name><name><surname>Knappskog</surname><given-names>S</given-names></name><name><surname>Tan</surname><given-names>BKT</given-names></name><name><surname>Jonkers</surname><given-names>J</given-names></name><name><surname>Borg</surname><given-names>Å</given-names></name><name><surname>Ueno</surname><given-names>NT</given-names></name><name><surname>Sotiriou</surname><given-names>C</given-names></name><name><surname>Viari</surname><given-names>A</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Span</surname><given-names>PN</given-names></name><name><surname>Van Laere</surname><given-names>S</given-names></name><name><surname>Lakhani</surname><given-names>SR</given-names></name><name><surname>Eyfjord</surname><given-names>JE</given-names></name><name><surname>Thompson</surname><given-names>AM</given-names></name><name><surname>Birney</surname><given-names>E</given-names></name><name><surname>Stunnenberg</surname><given-names>HG</given-names></name><name><surname>van de Vijver</surname><given-names>MJ</given-names></name><name><surname>Martens</surname><given-names>JWM</given-names></name><name><surname>Børresen-Dale</surname><given-names>A-L</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Kong</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Landscape of somatic mutations in 560 breast cancer whole-genome sequences</article-title><source>Nature</source><volume>534</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1038/nature17676</pub-id><pub-id pub-id-type="pmid">27135926</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nussenzweig</surname><given-names>A</given-names></name><name><surname>Nussenzweig</surname><given-names>MC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A backup DNA repair pathway moves to the forefront</article-title><source>Cell</source><volume>131</volume><fpage>223</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.10.005</pub-id><pub-id pub-id-type="pmid">17956720</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olivieri</surname><given-names>M</given-names></name><name><surname>Cho</surname><given-names>T</given-names></name><name><surname>Álvarez-Quilón</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Schellenberg</surname><given-names>MJ</given-names></name><name><surname>Zimmermann</surname><given-names>M</given-names></name><name><surname>Hustedt</surname><given-names>N</given-names></name><name><surname>Rossi</surname><given-names>SE</given-names></name><name><surname>Adam</surname><given-names>S</given-names></name><name><surname>Melo</surname><given-names>H</given-names></name><name><surname>Heijink</surname><given-names>AM</given-names></name><name><surname>Sastre-Moreno</surname><given-names>G</given-names></name><name><surname>Moatti</surname><given-names>N</given-names></name><name><surname>Szilard</surname><given-names>RK</given-names></name><name><surname>McEwan</surname><given-names>A</given-names></name><name><surname>Ling</surname><given-names>AK</given-names></name><name><surname>Serrano-Benitez</surname><given-names>A</given-names></name><name><surname>Ubhi</surname><given-names>T</given-names></name><name><surname>Feng</surname><given-names>S</given-names></name><name><surname>Pawling</surname><given-names>J</given-names></name><name><surname>Delgado-Sainz</surname><given-names>I</given-names></name><name><surname>Ferguson</surname><given-names>MW</given-names></name><name><surname>Dennis</surname><given-names>JW</given-names></name><name><surname>Brown</surname><given-names>GW</given-names></name><name><surname>Cortés-Ledesma</surname><given-names>F</given-names></name><name><surname>Williams</surname><given-names>RS</given-names></name><name><surname>Martin</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Durocher</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A genetic map of the response to DNA damage in human cells</article-title><source>Cell</source><volume>182</volume><fpage>481</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.05.040</pub-id><pub-id pub-id-type="pmid">32649862</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paculová</surname><given-names>H</given-names></name><name><surname>Kramara</surname><given-names>J</given-names></name><name><surname>Šimečková</surname><given-names>Š</given-names></name><name><surname>Fedr</surname><given-names>R</given-names></name><name><surname>Souček</surname><given-names>K</given-names></name><name><surname>Hylse</surname><given-names>O</given-names></name><name><surname>Paruch</surname><given-names>K</given-names></name><name><surname>Svoboda</surname><given-names>M</given-names></name><name><surname>Mistrík</surname><given-names>M</given-names></name><name><surname>Kohoutek</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>BRCA1 or CDK12 loss sensitizes cells to chk1 inhibitors</article-title><source>Tumour Biology</source><volume>39</volume><elocation-id>1010428317727479</elocation-id><pub-id pub-id-type="doi">10.1177/1010428317727479</pub-id><pub-id pub-id-type="pmid">29025359</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearl</surname><given-names>LH</given-names></name><name><surname>Schierz</surname><given-names>AC</given-names></name><name><surname>Ward</surname><given-names>SE</given-names></name><name><surname>Al-Lazikani</surname><given-names>B</given-names></name><name><surname>Pearl</surname><given-names>FMG</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Therapeutic opportunities within the DNA damage response</article-title><source>Nature Reviews. Cancer</source><volume>15</volume><fpage>166</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1038/nrc3891</pub-id><pub-id pub-id-type="pmid">25709118</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>G</given-names></name><name><surname>Dadiani</surname><given-names>M</given-names></name><name><surname>Kahana-Edwin</surname><given-names>S</given-names></name><name><surname>Pavlovski</surname><given-names>A</given-names></name><name><surname>Markus</surname><given-names>B</given-names></name><name><surname>Hornung</surname><given-names>G</given-names></name><name><surname>Balint-Lahat</surname><given-names>N</given-names></name><name><surname>Yosepovich</surname><given-names>A</given-names></name><name><surname>Hout-Siloni</surname><given-names>G</given-names></name><name><surname>Jacob-Hirsch</surname><given-names>J</given-names></name><name><surname>Sklair-Levy</surname><given-names>M</given-names></name><name><surname>Friedman</surname><given-names>E</given-names></name><name><surname>Barshack</surname><given-names>I</given-names></name><name><surname>Kaufman</surname><given-names>B</given-names></name><name><surname>Gal-Yam</surname><given-names>EN</given-names></name><name><surname>Paluch-Shimon</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Divergence of mutational signatures in association with breast cancer subtype</article-title><source>Molecular Carcinogenesis</source><volume>61</volume><fpage>1056</fpage><lpage>1070</lpage><pub-id pub-id-type="doi">10.1002/mc.23461</pub-id><pub-id pub-id-type="pmid">36111610</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeifer</surname><given-names>GP</given-names></name><name><surname>You</surname><given-names>YH</given-names></name><name><surname>Besaratinia</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mutations induced by ultraviolet light</article-title><source>Mutation Research</source><volume>571</volume><fpage>19</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.mrfmmm.2004.06.057</pub-id><pub-id pub-id-type="pmid">15748635</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pilarski</surname><given-names>R</given-names></name><name><surname>Carlo</surname><given-names>M</given-names></name><name><surname>Cebulla</surname><given-names>C</given-names></name><name><surname>Abdel-Rahman</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><source>BAP1 Tumor Predisposition Syndrome</source><publisher-name>University of Washington</publisher-name></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popova</surname><given-names>T</given-names></name><name><surname>Manié</surname><given-names>E</given-names></name><name><surname>Boeva</surname><given-names>V</given-names></name><name><surname>Battistella</surname><given-names>A</given-names></name><name><surname>Goundiam</surname><given-names>O</given-names></name><name><surname>Smith</surname><given-names>NK</given-names></name><name><surname>Mueller</surname><given-names>CR</given-names></name><name><surname>Raynal</surname><given-names>V</given-names></name><name><surname>Mariani</surname><given-names>O</given-names></name><name><surname>Sastre-Garau</surname><given-names>X</given-names></name><name><surname>Stern</surname><given-names>M-H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ovarian cancers harboring inactivating mutations in CDK12 display a distinct genomic instability pattern characterized by large tandem duplications</article-title><source>Cancer Research</source><volume>76</volume><fpage>1882</fpage><lpage>1891</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-2128</pub-id><pub-id pub-id-type="pmid">26787835</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priestley</surname><given-names>P</given-names></name><name><surname>Baber</surname><given-names>J</given-names></name><name><surname>Lolkema</surname><given-names>MP</given-names></name><name><surname>Steeghs</surname><given-names>N</given-names></name><name><surname>de Bruijn</surname><given-names>E</given-names></name><name><surname>Shale</surname><given-names>C</given-names></name><name><surname>Duyvesteyn</surname><given-names>K</given-names></name><name><surname>Haidari</surname><given-names>S</given-names></name><name><surname>van Hoeck</surname><given-names>A</given-names></name><name><surname>Onstenk</surname><given-names>W</given-names></name><name><surname>Roepman</surname><given-names>P</given-names></name><name><surname>Voda</surname><given-names>M</given-names></name><name><surname>Bloemendal</surname><given-names>HJ</given-names></name><name><surname>Tjan-Heijnen</surname><given-names>VCG</given-names></name><name><surname>van Herpen</surname><given-names>CML</given-names></name><name><surname>Labots</surname><given-names>M</given-names></name><name><surname>Witteveen</surname><given-names>PO</given-names></name><name><surname>Smit</surname><given-names>EF</given-names></name><name><surname>Sleijfer</surname><given-names>S</given-names></name><name><surname>Voest</surname><given-names>EE</given-names></name><name><surname>Cuppen</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Pan-Cancer whole-genome analyses of metastatic solid tumours</article-title><source>Nature</source><volume>575</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1689-y</pub-id><pub-id pub-id-type="pmid">31645765</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prolla</surname><given-names>TA</given-names></name><name><surname>Baker</surname><given-names>SM</given-names></name><name><surname>Harris</surname><given-names>AC</given-names></name><name><surname>Tsao</surname><given-names>JL</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Bronner</surname><given-names>CE</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Gordon</surname><given-names>M</given-names></name><name><surname>Reneker</surname><given-names>J</given-names></name><name><surname>Arnheim</surname><given-names>N</given-names></name><name><surname>Shibata</surname><given-names>D</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name><name><surname>Liskay</surname><given-names>RM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Tumour susceptibility and spontaneous mutation in mice deficient in MLH1, PMS1 and pms2 DNA mismatch repair</article-title><source>Nature Genetics</source><volume>18</volume><fpage>276</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/ng0398-276</pub-id><pub-id pub-id-type="pmid">9500552</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reitmair</surname><given-names>AH</given-names></name><name><surname>Schmits</surname><given-names>R</given-names></name><name><surname>Ewel</surname><given-names>A</given-names></name><name><surname>Bapat</surname><given-names>B</given-names></name><name><surname>Redston</surname><given-names>M</given-names></name><name><surname>Mitri</surname><given-names>A</given-names></name><name><surname>Waterhouse</surname><given-names>P</given-names></name><name><surname>Mittrücker</surname><given-names>HW</given-names></name><name><surname>Wakeham</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Msh2 deficient mice are viable and susceptible to lymphoid tumours</article-title><source>Nature Genetics</source><volume>11</volume><fpage>64</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1038/ng0995-64</pub-id><pub-id pub-id-type="pmid">7550317</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rekhtman</surname><given-names>N</given-names></name><name><surname>Montecalvo</surname><given-names>J</given-names></name><name><surname>Chang</surname><given-names>JC</given-names></name><name><surname>Alex</surname><given-names>D</given-names></name><name><surname>Ptashkin</surname><given-names>RN</given-names></name><name><surname>Ai</surname><given-names>N</given-names></name><name><surname>Sauter</surname><given-names>JL</given-names></name><name><surname>Kezlarian</surname><given-names>B</given-names></name><name><surname>Jungbluth</surname><given-names>A</given-names></name><name><surname>Desmeules</surname><given-names>P</given-names></name><name><surname>Beras</surname><given-names>A</given-names></name><name><surname>Bishop</surname><given-names>JA</given-names></name><name><surname>Plodkowski</surname><given-names>AJ</given-names></name><name><surname>Gounder</surname><given-names>MM</given-names></name><name><surname>Schoenfeld</surname><given-names>AJ</given-names></name><name><surname>Namakydoust</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>BT</given-names></name><name><surname>Rudin</surname><given-names>CM</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Travis</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas</article-title><source>Journal of Thoracic Oncology</source><volume>15</volume><fpage>231</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2019.10.023</pub-id><pub-id pub-id-type="pmid">31751681</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rentzsch</surname><given-names>P</given-names></name><name><surname>Witten</surname><given-names>D</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name><name><surname>Shendure</surname><given-names>J</given-names></name><name><surname>Kircher</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cadd: predicting the deleteriousness of variants throughout the human genome</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D886</fpage><lpage>D894</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1016</pub-id><pub-id pub-id-type="pmid">30371827</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rescigno</surname><given-names>P</given-names></name><name><surname>Gurel</surname><given-names>B</given-names></name><name><surname>Pereira</surname><given-names>R</given-names></name><name><surname>Crespo</surname><given-names>M</given-names></name><name><surname>Rekowski</surname><given-names>J</given-names></name><name><surname>Rediti</surname><given-names>M</given-names></name><name><surname>Barrero</surname><given-names>M</given-names></name><name><surname>Mateo</surname><given-names>J</given-names></name><name><surname>Bianchini</surname><given-names>D</given-names></name><name><surname>Messina</surname><given-names>C</given-names></name><name><surname>Fenor de la Maza</surname><given-names>MD</given-names></name><name><surname>Chandran</surname><given-names>K</given-names></name><name><surname>Carmichael</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>C</given-names></name><name><surname>Paschalis</surname><given-names>A</given-names></name><name><surname>Sharp</surname><given-names>A</given-names></name><name><surname>Seed</surname><given-names>G</given-names></name><name><surname>Figueiredo</surname><given-names>I</given-names></name><name><surname>Lambros</surname><given-names>M</given-names></name><name><surname>Miranda</surname><given-names>S</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name><name><surname>Bertan</surname><given-names>C</given-names></name><name><surname>Riisnaes</surname><given-names>R</given-names></name><name><surname>Porta</surname><given-names>N</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><name><surname>Carreira</surname><given-names>S</given-names></name><name><surname>de Bono</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Characterizing CDK12-mutated prostate cancers</article-title><source>Clinical Cancer Research</source><volume>27</volume><fpage>566</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-2371</pub-id><pub-id pub-id-type="pmid">32988971</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauter</surname><given-names>JL</given-names></name><name><surname>Graham</surname><given-names>RP</given-names></name><name><surname>Larsen</surname><given-names>BT</given-names></name><name><surname>Jenkins</surname><given-names>SM</given-names></name><name><surname>Roden</surname><given-names>AC</given-names></name><name><surname>Boland</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior</article-title><source>Modern Pathology</source><volume>30</volume><fpage>1422</fpage><lpage>1432</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2017.61</pub-id><pub-id pub-id-type="pmid">28643792</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>VK</given-names></name><name><surname>Rastogi</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>De</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mutational signature SBS8 predominantly arises due to late replication errors in cancer</article-title><source>Communications Biology</source><volume>3</volume><elocation-id>421</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-020-01119-5</pub-id><pub-id pub-id-type="pmid">32747711</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Sørensen</surname><given-names>SG</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>DDR_Predict</data-title><version designator="swh:1:rev:c4daf1b7a9526ea411ad763c05d0c9317b45d42e">swh:1:rev:c4daf1b7a9526ea411ad763c05d0c9317b45d42e</version><source>Software Heritage</source><ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:b7a8bcef96a3427ab3cffebcd972f928b90a126f;origin=https://github.com/SimonGrund/DDR_Predict;visit=swh:1:snp:5ebc529b45f19267e9a399beedc0e74404b80f8e;anchor=swh:1:rev:c4daf1b7a9526ea411ad763c05d0c9317b45d42e">https://archive.softwareheritage.org/swh:1:dir:b7a8bcef96a3427ab3cffebcd972f928b90a126f;origin=https://github.com/SimonGrund/DDR_Predict;visit=swh:1:snp:5ebc529b45f19267e9a399beedc0e74404b80f8e;anchor=swh:1:rev:c4daf1b7a9526ea411ad763c05d0c9317b45d42e</ext-link></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sumanasuriya</surname><given-names>S</given-names></name><name><surname>De Bono</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Treatment of advanced prostate cancer-a review of current therapies and future promise</article-title><source>Cold Spring Harbor Perspectives in Medicine</source><volume>8</volume><elocation-id>a030635</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a030635</pub-id><pub-id pub-id-type="pmid">29101113</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tate</surname><given-names>JG</given-names></name><name><surname>Bamford</surname><given-names>S</given-names></name><name><surname>Jubb</surname><given-names>HC</given-names></name><name><surname>Sondka</surname><given-names>Z</given-names></name><name><surname>Beare</surname><given-names>DM</given-names></name><name><surname>Bindal</surname><given-names>N</given-names></name><name><surname>Boutselakis</surname><given-names>H</given-names></name><name><surname>Cole</surname><given-names>CG</given-names></name><name><surname>Creatore</surname><given-names>C</given-names></name><name><surname>Dawson</surname><given-names>E</given-names></name><name><surname>Fish</surname><given-names>P</given-names></name><name><surname>Harsha</surname><given-names>B</given-names></name><name><surname>Hathaway</surname><given-names>C</given-names></name><name><surname>Jupe</surname><given-names>SC</given-names></name><name><surname>Kok</surname><given-names>CY</given-names></name><name><surname>Noble</surname><given-names>K</given-names></name><name><surname>Ponting</surname><given-names>L</given-names></name><name><surname>Ramshaw</surname><given-names>CC</given-names></name><name><surname>Rye</surname><given-names>CE</given-names></name><name><surname>Speedy</surname><given-names>HE</given-names></name><name><surname>Stefancsik</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>SL</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>S</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Forbes</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cosmic: the Catalogue of somatic mutations in cancer</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D941</fpage><lpage>D947</lpage><pub-id pub-id-type="doi">10.1093/nar/gky1015</pub-id><pub-id pub-id-type="pmid">30371878</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trizzino</surname><given-names>M</given-names></name><name><surname>Barbieri</surname><given-names>E</given-names></name><name><surname>Petracovici</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Welsh</surname><given-names>SA</given-names></name><name><surname>Owens</surname><given-names>TA</given-names></name><name><surname>Licciulli</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><name><surname>Gardini</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The tumor suppressor ARID1A controls global transcription via pausing of RNA polymerase II</article-title><source>Cell Reports</source><volume>23</volume><fpage>3933</fpage><lpage>3945</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2018.05.097</pub-id><pub-id pub-id-type="pmid">29949775</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umar</surname><given-names>A</given-names></name><name><surname>Boyer</surname><given-names>JC</given-names></name><name><surname>Thomas</surname><given-names>DC</given-names></name><name><surname>Nguyen</surname><given-names>DC</given-names></name><name><surname>Risinger</surname><given-names>JI</given-names></name><name><surname>Boyd</surname><given-names>J</given-names></name><name><surname>Ionov</surname><given-names>Y</given-names></name><name><surname>Perucho</surname><given-names>M</given-names></name><name><surname>Kunkel</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>14367</fpage><lpage>14370</lpage><pub-id pub-id-type="doi">10.1016/S0021-9258(17)36630-9</pub-id><pub-id pub-id-type="pmid">8182040</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umar</surname><given-names>A</given-names></name><name><surname>Boland</surname><given-names>CR</given-names></name><name><surname>Terdiman</surname><given-names>JP</given-names></name><name><surname>Syngal</surname><given-names>S</given-names></name><name><surname>de la Chapelle</surname><given-names>A</given-names></name><name><surname>Rüschoff</surname><given-names>J</given-names></name><name><surname>Fishel</surname><given-names>R</given-names></name><name><surname>Lindor</surname><given-names>NM</given-names></name><name><surname>Burgart</surname><given-names>LJ</given-names></name><name><surname>Hamelin</surname><given-names>R</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><name><surname>Hiatt</surname><given-names>RA</given-names></name><name><surname>Jass</surname><given-names>J</given-names></name><name><surname>Lindblom</surname><given-names>A</given-names></name><name><surname>Lynch</surname><given-names>HT</given-names></name><name><surname>Peltomaki</surname><given-names>P</given-names></name><name><surname>Ramsey</surname><given-names>SD</given-names></name><name><surname>Rodriguez-Bigas</surname><given-names>MA</given-names></name><name><surname>Vasen</surname><given-names>HFA</given-names></name><name><surname>Hawk</surname><given-names>ET</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Freedman</surname><given-names>AN</given-names></name><name><surname>Srivastava</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability</article-title><source>Journal of the National Cancer Institute</source><volume>96</volume><fpage>261</fpage><lpage>268</lpage><pub-id pub-id-type="doi">10.1093/jnci/djh034</pub-id><pub-id pub-id-type="pmid">14970275</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkova</surname><given-names>NV</given-names></name><name><surname>Meier</surname><given-names>B</given-names></name><name><surname>González-Huici</surname><given-names>V</given-names></name><name><surname>Bertolini</surname><given-names>S</given-names></name><name><surname>Gonzalez</surname><given-names>S</given-names></name><name><surname>Vöhringer</surname><given-names>H</given-names></name><name><surname>Abascal</surname><given-names>F</given-names></name><name><surname>Martincorena</surname><given-names>I</given-names></name><name><surname>Campbell</surname><given-names>PJ</given-names></name><name><surname>Gartner</surname><given-names>A</given-names></name><name><surname>Gerstung</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mutational signatures are jointly shaped by DNA damage and repair</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2169</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15912-7</pub-id><pub-id pub-id-type="pmid">32358516</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>von Bueren</surname><given-names>AO</given-names></name><name><surname>Bacolod</surname><given-names>MD</given-names></name><name><surname>Hagel</surname><given-names>C</given-names></name><name><surname>Heinimann</surname><given-names>K</given-names></name><name><surname>Fedier</surname><given-names>A</given-names></name><name><surname>Kordes</surname><given-names>U</given-names></name><name><surname>Pietsch</surname><given-names>T</given-names></name><name><surname>Koster</surname><given-names>J</given-names></name><name><surname>Grotzer</surname><given-names>MA</given-names></name><name><surname>Friedman</surname><given-names>HS</given-names></name><name><surname>Marra</surname><given-names>G</given-names></name><name><surname>Kool</surname><given-names>M</given-names></name><name><surname>Rutkowski</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours</article-title><source>British Journal of Cancer</source><volume>107</volume><fpage>1399</fpage><lpage>1408</lpage><pub-id pub-id-type="doi">10.1038/bjc.2012.403</pub-id><pub-id pub-id-type="pmid">22976800</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y-M</given-names></name><name><surname>Cieślik</surname><given-names>M</given-names></name><name><surname>Lonigro</surname><given-names>RJ</given-names></name><name><surname>Vats</surname><given-names>P</given-names></name><name><surname>Reimers</surname><given-names>MA</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Ning</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Kunju</surname><given-names>LP</given-names></name><name><surname>de Sarkar</surname><given-names>N</given-names></name><name><surname>Heath</surname><given-names>EI</given-names></name><name><surname>Chou</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>FY</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>de Bono</surname><given-names>JS</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Montgomery</surname><given-names>B</given-names></name><name><surname>Alva</surname><given-names>A</given-names></name><collab>PCF/SU2C International Prostate Cancer Dream Team</collab><name><surname>Robinson</surname><given-names>DR</given-names></name><name><surname>Chinnaiyan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer</article-title><source>Cell</source><volume>173</volume><fpage>1770</fpage><lpage>1782</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.04.034</pub-id><pub-id pub-id-type="pmid">29906450</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Meehan</surname><given-names>B</given-names></name><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>XQD</given-names></name><name><surname>Fiset</surname><given-names>PO</given-names></name><name><surname>Rieker</surname><given-names>R</given-names></name><name><surname>Levins</surname><given-names>C</given-names></name><name><surname>Kong</surname><given-names>T</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Morin</surname><given-names>G</given-names></name><name><surname>Skerritt</surname><given-names>L</given-names></name><name><surname>Herpel</surname><given-names>E</given-names></name><name><surname>Venneti</surname><given-names>S</given-names></name><name><surname>Martinez</surname><given-names>D</given-names></name><name><surname>Judkins</surname><given-names>AR</given-names></name><name><surname>Jung</surname><given-names>S</given-names></name><name><surname>Camilleri-Broet</surname><given-names>S</given-names></name><name><surname>Gonzalez</surname><given-names>AV</given-names></name><name><surname>Guiot</surname><given-names>MC</given-names></name><name><surname>Lockwood</surname><given-names>WW</given-names></name><name><surname>Spicer</surname><given-names>JD</given-names></name><name><surname>Agaimy</surname><given-names>A</given-names></name><name><surname>Pastor</surname><given-names>WA</given-names></name><name><surname>Dostie</surname><given-names>J</given-names></name><name><surname>Rak</surname><given-names>J</given-names></name><name><surname>Foulkes</surname><given-names>WD</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Smarca4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>557</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08380-1</pub-id><pub-id pub-id-type="pmid">30718506</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81224.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rathmell</surname><given-names>W Kimryn</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dq2gs74</institution-id><institution>Vanderbilt University Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.01.31.478445" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.01.31.478445"/></front-stub><body><p>This is a well-motivated study looking at the association of DNA repair deficiencies with mutational patterns. This study is of interest to the cancer genomics community and highlights how the understanding of DNA repair processes can be used in the development of novel cancer therapy, and will also be of interest to researchers in the field of genomic medicine and cancer mutagenesis. It presents predictive models with potential clinical applications that can identify patients with specific gene dysfunction based on characteristic patterns of mutation. The key findings are well supported.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81224.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Rathmell</surname><given-names>W Kimryn</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05dq2gs74</institution-id><institution>Vanderbilt University Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.01.31.478445">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.01.31.478445v2">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and W Kimryn Rathmell as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Below you will find several suggestions for text changes that will improve the clarity of the manuscript. We encourage you to consider these suggestions and ask that you provide a response indicating how you have addressed those that you agree have merit in the text.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>Some open questions and comments follow.</p><p>The authors mention that they excluded age-related signature 1 from the modeling as a potential confounder. Given this issue, I wondered why the clocklike signature SBS5 was not excluded for the same reason.</p><p>Monte Carlo simulation to test the performance of the lasso is mentioned twice in the main text but appears not to be described in the methods.</p><p>Regarding spurious LOFs potentially driving models in some colorectal subsets, I question why hypermutated samples were not screened ahead of modeling or further QC of variant calls from HMF and PCAWG performed.</p><p>At various points in the manuscript, the authors emphasise which models are predictive across primary and metastatic samples. This is interesting. It would have been useful to see these points consolidated in a single section of the text or a figure to allow readers to consider which deficiency models are generalizable across tumours of different metastatic potentials. Do the authors have a hypothesis as to why this might be? Where models are not generalizable is this down to insufficient power or because there is an alteration in the mode of damage associated with that deficiency in mets?</p><p>Re SMARCA4-d in tumours of unknown primary with SMARCA4 WT, is it established that there is no epigenetic silencing event in these cases?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>A well-motivated paper using various computational analyses and a pan-cancer data set to decipher DDR genes that may be used for clinical intervention after</p><p>extensive validation.</p><p>There are a few questions that need to be addressed, as outlined below:</p><p>Despite the association between BRCA genes and mutation signature 3, previous studies have suggested that lesions in PALB2 and RAD51-related genes might contribute to mutational signature 3 activity. It would be interesting to figure out why these genes were not detected by the model.</p><p>How does the damage in DDR genes differ between patients?</p><p>I would recommend that the authors perform univariate and multivariate Cox proportional hazard models to explore associations of biomarkers (24 genes) with PFS, DSS, or OS.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81224.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>Some open questions and comments follow.</p><p>The authors mention that they excluded age-related signature 1 from the modeling as a potential confounder. Given this issue, I wondered why the clocklike signature SBS5 was not excluded for the same reason.</p></disp-quote><p>We thank the reviewer for noting the recent updates to the COSMIC annotation of the mutational signature 5, which is now listed as potentially associated with time/age. Previously, signature five was not associated clearly with time/age, and has been suggested to be associated with other DNA damage response processes including the hormone receptor positive subtype of breast cancers. We have clarified this in the manuscript, Materials and methods subsection: “Mutational patterns of single base substitutions, indels and structural variants”:</p><p>“We did not exclude signature 5 although it has suggested association with age, because it also has suggested associations to the hormone receptor positive subtype of breast cancers(Perry et al. 2022)”</p><disp-quote content-type="editor-comment"><p>Monte Carlo simulation to test the performance of the lasso is mentioned twice in the main text but appears not to be described in the methods.</p></disp-quote><p>This was a textual error on our part and we thank the reviewer for making us aware the structure was unclear. The Monte Carlo simulations are described in the Materials and methods subsection: “Model selection”. To make this clear, we have retitled the subsection to: “Model selection using Monte Carlo simulations”, and updated the text to make it more evident to the reader.</p><disp-quote content-type="editor-comment"><p>Regarding spurious LOFs potentially driving models in some colorectal subsets, I question why hypermutated samples were not screened ahead of modeling or further QC of variant calls from HMF and PCAWG performed.</p></disp-quote><p>We agree with the reviewer that hypermutated cancers present a challenge for an automated and generic modeling procedure. In particular, they may harbor large numbers of LOF events, many of which may be inconsequential for cancer evolution. (We have now included an overview of the number of LOF events per tumour (Figure 1—figure supplement 1), which helps illustrate this.) We decided to include hypermutated tumours to ensure a uniform application and evaluation of our generic procedure, and since genetic hypermutator phenotypes are well described among colorectal cancers. Given that our procedure separates samples by cancer type, hypermutated colorectal cancers samples would not affect models trained for other cancer types.</p><p>Inspired by the comment from the reviewer, we evaluated the enrichment of LOF mutations among the subset of hypermutated tumors and now include a paragraph on this in the subsection: “Colorectal cancer models derived from hypermutated mismatch repair deficient tumours”:</p><p>“The high number of models of monoallelic deficiencies may arise from spurious LOF events in DDR genes in a subset of colorectal cancers that are hypermutated. In line with this, the hypermutated samples (n=18; &gt;100,000 mutations) harbour 22% (5.9 fold enrichment) of all the DDR LOF events across the HMF colorectal cancer samples (n=475).”</p><p>We further reran our predictive modeling pipeline with exclusion of these hypermutated colorectal tumor samples. However, no DDR genes then had LOF sets sufficiently large to fulfill our modeling criteria (n&lt;8 in all cases). We would thus be unable to detect the <italic>MSH3</italic>-d model or any of the other models among the colorectal cancer samples. We did not include these results in the manuscript.</p><p>In terms of the risk of false variant calls, our setup relies on the extensive quality control performed by the PCAWG and the Hartwig Medical Foundation and thus on the tradeoff between sensitivity and specificity chosen for their variant calling. This tradeoff relies on access to BAM files and extensive experimentation, which was not the focus of our study and thus out of scope. Importantly, mutational signatures are generally robust towards false mutation calls as long as they are not systematic; this has been extensively considered for the HMF and PCAWG data specifically (PCAWG: (Alexandrov et al. 2020); HMF: (Degasperi et al. 2020)).</p><disp-quote content-type="editor-comment"><p>At various points in the manuscript, the authors emphasise which models are predictive across primary and metastatic samples. This is interesting. It would have been useful to see these points consolidated in a single section of the text or a figure to allow readers to consider which deficiency models are generalizable across tumours of different metastatic potentials. Do the authors have a hypothesis as to why this might be? Where models are not generalizable is this down to insufficient power or because there is an alteration in the mode of damage associated with that deficiency in mets?</p></disp-quote><p>We agree with the reviewer that it may be of general interest to include an overview of the performance of each model across metastatic and primary tumours. We have expanded our analysis to include a unified overview of the predictive power in the opposite data set. These results are now provided in Supplementary File 1h and summarized in Figure 3—figure supplement 1. We provide introduce this analysis and the models that have significant predictive power in the opposite data in a short separate Results’ subsection: “Testing models in the opposite data set” (and include a corresponding Methods’ subsection):</p><p>“Additionally, we calculated the PR-AUC-E of each model when applied to the same cohort in the opposite data set (Figure 3—figure supplement 1). Due to the difference in biology between the two sets, and low numbers of LOF mutated samples, we did not use this as a model performance criteria but have included the PR-AUC-E values and p-values from the tests (Supplementary File 1h). We identified significant predictive power, across both metastatic and primary cancers, for deficiency models of BRCA1/2, TP53, CDK12, PTEN, ARID1A, and IDH1A. Each case is described in the respective part of the results.”</p><p>Notably, the currently available data sets are not well suited to pinpoint systematic differences between metastatic and primary tumours due to varying cohort sizes of different cancer types within and between the two data sets. Many models cannot be evaluated in other cancer types or the opposite data set due to lack of samples with mutations in a given DDR gene. Thus, we cannot exclude that more models may have predictive power between both metastatic and primary cancers than what we can currently identify.</p><disp-quote content-type="editor-comment"><p>Re SMARCA4-d in tumours of unknown primary with SMARCA4 WT, is it established that there is no epigenetic silencing event in these cases?</p></disp-quote><p>We do not have access to epigenetic data from the tumours of unknown primary, but were able to access expression data for a subset of them (58 of 77). Expression analysis did not indicate that epigenetic silencing was taking place, which we now show in Figure 6k and state in the subsection: “Predictive model for SMARCA4-d in cancer of unknown primary”:</p><p>“We evaluated the expression of SMARCA4 among the cancers of unknown primary and identified a significantly lower expression of SMARCA4 in tumours with biallelic LOF mutations compared to wild type (p=0.54x10<sup>-2</sup>; Figure 6k). For the 12 tumours with high signature 27 exposure but no biallelic LOF mutations, we did not observe a similar decrease in expression (Figure 6k), suggesting that SMARCA4 was not epigenetically silenced or otherwise transcriptionally inactivated in these cases.”</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>A well-motivated paper using various computational analyses and a pan-cancer data set to decipher DDR genes that may be used for clinical intervention after</p><p>extensive validation.</p><p>There are a few questions that need to be addressed, as outlined below:</p><p>Despite the association between BRCA genes and mutation signature 3, previous studies have suggested that lesions in PALB2 and RAD51-related genes might contribute to mutational signature 3 activity. It would be interesting to figure out why these genes were not detected by the model.</p></disp-quote><p>We agree with the reviewer that it is reasonable to expect associations between <italic>PALB2</italic> and <italic>RAD51</italic> and signature 3. However, we did not have sufficient data to evaluate this as we only identified a single patient with a LOF mutation in <italic>RAD51</italic> and a single in <italic>PALB2</italic> across all breast cancer samples of both data sets.</p><disp-quote content-type="editor-comment"><p>How does the damage in DDR genes differ between patients?</p></disp-quote><p>We have included Supplementary File 1g, which summarizes the types of DDR gene damages across the samples included for the training of each predictive model. Additionally, we now include Figure 1—figure supplement 1, which shows the rate of LOF events in DDR genes at a per-tumour level. To preserve patient privacy and the data agreements, we cannot present DDR gene damages at an individual sample level. We now detail this in the Materials and methods section, subsection: “Annotating biallelic and monoallelic gene hits”:</p><p>“We have summarised the causes of LOF annotation at a per-model basis (Supplementary File 1g), including an annotation of the number of tumours with events hotspot locations, microhomologous DNA, and repetitive DNA. We do not disclose this information at a per-sample level in order to maintain patient privacy and data safety.“</p><disp-quote content-type="editor-comment"><p>I would recommend that the authors perform univariate and multivariate Cox proportional hazard models to explore associations of biomarkers (24 genes) with PFS, DSS, or OS.</p></disp-quote><p>We agree that it is of general interest to understand the association between DDR deficiencies and survival, though we have low numbers of LOF mutated samples in most cases as well as missing survival data in some cases, and thus limited statistical power for detecting significant hazard associations.</p><p>We have now included Kaplan-Meier plots and the results of fitting univariate Cox-regression models to overall survival statistics (the only type we have available). The results are reported in the Results’ subsection “Survival analysis” with a full summary given in Figure 3—figure supplement 1 and individual Kaplan-Meier plots shown in Figure 3—figure supplement 2:</p><p>“For each of the shortlisted models, we evaluated the difference in overall survival between samples carrying LOF mutations and those that did not. We observed nominally significant differences (p&lt;0.05; univariate Cox regression analysis) in survival for BRCA2 and TP53 in multiple cancer types as well as for UVRAG in colorectal cancer (Figure 3—figure supplement 1,2 Supplementary file 1j). The association of TP53 monoallelic LOF with decreased survival is in line with expectations<sup>29</sup>. Interestingly, several models of BRCA1/2 LOF mutations associated with improved survival, including BRCA1 LOF mutations in metastatic ovary cancers (HR&lt;0.42; p&lt;0.093) and BRCA2 LOF mutations in non-metastatic ovary cancers (HR&lt;0.24;p&lt;0.017). In contrast, BRCA2 LOF mutations in primary breast cancers were associated with decreased survival (HR&gt;9.30; p&lt;0.004). This may potentially reflect differences in both molecular diagnostic practices and treatment regiments across these cancer types. For instance, platin-based treatment irrespective of BRCA1/2 status has been standard for groups of the ovarian and pancreatic cancer patients, while traditionally not for the breast cancer patients<sup>30,31</sup>. The sensitising effect of BRCA1/2 deficiency might thus explain the associated survival differences among cancer types<sup>32</sup>. For most models the differences in survival were insignificant, though this may be related to the generally small set of LOF mutated samples.”</p><p>We have not extended this analysis further given the general small number of LOF mutated samples and resulting issues with lack of power.</p></body></sub-article></article>